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ABSTRACT 
 
Very long chain acyl-coA dehydrogenase (VLCAD) is the rate-limiting step 
in mitochondrial fatty acid oxidation. VLCAD deficient mice and patients’ clinical 
symptoms stem from not only an energy deficiency but also long-chain 
metabolite accumulations.  VLCAD deficient mice were treated systemically with 
1x1012 vector genomes of rAAV9-VLCAD.  Expression was detected in the liver, 
heart and muscle.  Also substantial expression of VLCAD was noted in the brain, 
where it was expressed across different sections of the brain and in different cell 
types with different morphologies.  Biochemical correction was observed in 
vector-treated mice beginning two weeks post-injection, as characterized by a 
significant drop in long chain fatty acyl accumulates in whole blood after an 
overnight fast. Changes persisted through the termination point around 20 weeks 
post injection. Magnetic resonance spectroscopy (MRS) and tandem mass 
spectrometry (MS/MS) revealed normalization of intramuscular lipids in treated 
animals.  Correction was not observed in liver tissue extracts, but cardiac muscle 
extracts showed significant reduction of long chain metabolites.  Disease-specific 
phenotypes were characterized, including thermoregulation and maintenance of 
euglycemia after a fasting cold challenge.  Internal body temperatures of 
untreated VLCAD-/- mice dropped below 20°C and the mice became lethargic, 
requiring euthanasia. In contrast all rAAV9-treated VLCAD-/- mice and the wild-
type controls maintained body temperatures.  rAAV9-treated VLCAD-/- mice 
maintained euglycemia, whereas untreated VLCAD-/- mice suffered 
hypoglycemia following a fasting cold challenge. These promising results suggest 
rAAV9 gene therapy as a potential treatment for VLCAD deficiency in humans. 
 
  
vi
 
TABLE OF CONTENTS 
 
SIGNATURE PAGE ............................................................................... ii 
DEDICATION ......................................................................................... iii 
ACKNOWLEDGEMENTS ...................................................................... iv 
ABSTRACT ............................................................................................ v 
TABLE OF CONTENTS ......................................................................... vi 
LIST OF TABLES .................................................................................. vii 
LIST OF FIGURES ................................................................................ viii-ix 
LIST OF ABBREVIATIONS ................................................................... x 
LIST OF MULTIMEDIA FILES ............................................................... xi 
PREFACE .............................................................................................. xii-xiii 
CHAPTER I: Introduction to Mitochondrial Fatty Acid Oxidation and Defects in 
Mitochondrial Fatty Acid Oxidation ........................................................ 1-21 
CHAPTER II:  Introduction to Gene Therapy for Beta-Oxidation  
Disorders ............................................................................................... 22-30 
CHAPTER III: Gene Therapy for VLCAD- Transduction and Expression 
 ............................................................................................................... 31-43 
CHAPTER IV: Transduction of Brain after Systemic Injection ............... 45-67 
CHAPTER V: Gene Therapy for VLCAD- Biochemical and Phenotypic  
Correction .............................................................................................. 68-104 
CHAPTER VI: Discussion ...................................................................... 105-111 
CHAPTER VII: Additional Projects- Aberrant Immune Responses in  
CFTR-/- mice ......................................................................................... 112-139 
CHAPTER VIII: Additional Projects- IL-13 and IL-17e Receptor  
Therapy .................................................................................................. 140-169 
FINAL REMARKS .................................................................................. 170 
BIBLOGRAPHY ..................................................................................... 171-200 
 
 
 
vii
 
LIST OF TABLES 
 
Table 8.1 Proportions of inflammatory cells in the BAL ......................... 160 
 
  
viii
LIST OF FIGURES 
Figure 1.1 Transport and Oxidation of Long Chain Fatty Acids in the  
Mitochondria .......................................................................................... 3 
Figure 3.1 Transduction of rAAV9-VLCAD ............................................ 36 
Figure 3.2 Expression of rAAV9-VLCAD ............................................... 37 
Figure 3.3 Inflammation of Liver Post-injection ...................................... 39-40 
Figure 3.4 Expression differences of rAAV9-VLCAD in Male and  
Female mice .......................................................................................... 41 
Figure 4.1 AAV9 mediated VLCAD Expression in Cell types with Different  
Morphologies ......................................................................................... 51 
Figure 4.2 AAV9 mediated VLCAD Expression in the Hippocampus .... 52 
Figure 4.3 AAV9 mediated VLCAD Expression in the Cerebellum ........ 53 
Figure 4.4 AAV9 mediated VLCAD Expression in the Choroid Plexus .. 54 
Figure 4.5 Expression of VLCAD in different Mouse Strains in the Brain 55 
Figure 4.6 AAV9 mediated VLCAD Transduction in the brain of different  
Mouse Strains ........................................................................................ 56 
Figure 4.7 AAV9 mediated VLCAD Expression at different time points  
post-injection .......................................................................................... 58 
Figure 4.8 Comparison of Transduction in mice injected with different  
transgenes ............................................................................................. 59 
Figure 4.9 VLCAD and GFP expression in different tissues .................. 60 
Figure 4.10 AAV9 Transduction comparison of VLCAD and GFP in different 
Tissues .................................................................................................. 62 
Figure 4.11 Neuronal Expression of VLCAD by Confocal Microscopy .. 64-65 
Figure 5.1 Reduction of Acyl Carnitines in the blood of  rAAV9-VLCAD  
treated mice ........................................................................................... 73 
Figure 5.2 Levels of Acyl Carnitines in rAAV9 with GFP control ........... 75-76 
Figure 5.3 Acyl Carnitine Profiles in the blood of in uninjected mice  
over time ................................................................................................ 77-78 
Figure 5.4 MS/MS quantification of C16 in the whole blood over time .. 79 
Figure 5.5 MS/MS quantification of C18:1 in the whole blood over time 80 
Figure 5.6 MS/MS quantification of C18 in the whole blood over time .. 81 
Figure 5.7 Biochemical analysis of lipids in the liver in vivo .................. 82 
Figure 5.8 Biochemical analysis of Acyl Carnitines in the liver ex vivo .. 83 
Figure 5.9 Biochemical analysis of lipids in the muscle of in vivo .......... 85-86 
Figure 5.10 Biochemical analysis of Acyl Carnitines in the muscle  
ix
ex vivo .................................................................................................... 87-88 
Figure 5.11 Reduction of Acyl Carnitines in the heart ........................... 90 
Figure 5.12 Temperature maintenance and survival of rAAV9-VLCAD  
treated mice after cold fast challenge .................................................... 91-92 
Figure 5.13 Maintenance of blood glucose in rAAV9-VLCAD treated mice after 
cold fast challenge ................................................................................. 94 
Figure 5.14 MS/MS quantification of C16 in the whole blood  
over time in Female mice ....................................................................... 96 
Figure 5.15 Temperature and Survival of Female rAAV9-treated mice after  
cold fast challenge ................................................................................. 97-98 
Figure 5.16 Blood glucose in Female rAAV9-VLCAD treated mice after 
cold fast challenge ................................................................................. 100 
Figure 7.1 Total serum IgE levels in congenic C57B6 CFTR-/- mice and  
their littermates after Af sensitization and challenge ............................. 118 
Figure 7.2 Adoptive transfer of CF splenocytes confers elevated IgE  
Phenotype .............................................................................................. 120-121 
Figure 7.3 In vitro antigen recall with mixed cell populations ................. 123-124 
Figure 7.4 Total serum IgE levels in naïve conditional CFTR-/- mice .... 126 
Figure 7.5 Total serum IgE levels in Af-cpe-sensitized conditional  
CFTR -/- mice ........................................................................................ 127 
Figure 7.6 Intracellular calcium (iCa2+) flux .......................................... 129-130 
Figure 7.7 NFATc1 nuclear translocation and cytokine secretion in Cftr-/- and 
Cftr+/+ mice after T cell receptor stimulation ......................................... 131-132 
Figure 8.1 Overexpression of IL-13 in Cftr-deficient mice after ABPA ... 150 
Figure 8.2 IL-17Rh1Fc fusion protein is stable and efficiently secreted 152-153 
Figure 8.3 Binding capacity of IL-17RhFc .............................................. 155 
Figure 8.4 Reduction in circulating IgE levels after soluble receptor  
therapy ................................................................................................... 157 
Figure 8.5 Cytokine levels in the BAL of mice treated with rAAV1 expression:  
IL-13RαFc, IL-17Rh1Fc or mSCAD ....................................................... 159 
Figure 8.6 Intracellular cytokines produced after receptor agonist  
treatment ................................................................................................ 161 
Figure 8.7 Expression of IL-17e in CD14+ and CD4+ cells ................... 163 
Figure 8.8 Model of IL-17e and IL-13 Receptor Therapy ....................... 168 
 
  
x
LIST OF ABBREVIATIONS 
 
FAO- Fatty-acid oxidation 
CoA- Coenzyme A 
Carnitine palmitoyltransferase-1 
(CPT-1) 
Carnitine palmitoyltransferase-2 
(CPT-2) 
Acyl-CoA dehydrogenases (ACADs) 
Adenine Tri-phosphate (ATP) 
Nicotinamide adenine dinucleotide 
(NAD+) 
Flavin adenine dinucleotide(FAD) 
Electron transferring flavoprotein 
(ETF) 
Very long chain acyl-coA 
dehydrogenase (VLCAD) 
Long chain acyl-coA dehydrogenase 
(LCAD) 
Medium chain acyl-coA 
dehydrogenase (MCAD) 
Short chain acyl-coA dehydrogenase 
(SCAD) 
Tandem mass-spectrometry 
(MS/MS) 
Sudden infant death syndrome 
(SIDS) 
Medium-chain triglycerides (MCT) 
Long-chain 3-hydroxyacyl CoA 
dehydrogenase (LCHAD) 
Peroxisome proliferator-activated 
receptors (PPARs) 
Messenger ribonucleic acid- (mRNA) 
Mitochondrial trifunctional protein 
(mTFP) 
Adeno associated virus (AAV) 
Inverted terminal repeats (ITR) 
Kilobases (kb) 
Ribonucleic acid interference (RNAi) 
Genomic deoxyribonucleic acid 
(gDNA) 
Tibialis anterior (TA) 
Chicken Beta Actin Promoter (CBA) 
Phosphate Buffered Solution (PBS) 
Vector genomes (vg) 
Nuclear factor kappa-light-chain-
enhancer of activated B cells (NFkB) 
Blood brain barrier (BBB) 
Green Fluorescent Protein (GFP) 
Neuronal specific class III beta-
tubulin (Tuj-1) 
Single voxel proton magnetic 
resonance spectroscopy (1H-MRS) 
Extensor digitorum longus (EDL) 
Soleus (SOL) 
Uncoupling protein 1 (UCP-1) 
Cystic Fibrosis (CF) 
Cystic fibrosis transmembrane 
regulator (CFTR) 
Interleukin (IL) 
Keratineocyte derived chemokine 
(KC) 
Macrophage inflammatory protein-2 
(MIP2) 
Allergic broncho-pulmonary 
aspergillosis (ABPA) 
T helper 2 lymphocyte (Th2) 
Immunoglobulin (Ig) 
Aspergillus fumigatus (Af) 
Nuclear factor of activated T-cells 
(NFAT) 
 
 
 
 
 
  
xi
 
 
LIST OF MULTIMEDIA OBJECTS OR FILES 
 
Video 5.1 Representative video of VLCAD-/- PBS control mouse after 18hr fast 
and 120 minutes at 4°C 
Video 5.2 Representative video of VLCAD -/- rAAV9 treated mouse after 18hr 
fast and 120 minutes at 4°C 
Video 5.3 Representative video of VLCAD +/+ PBS treated mouse after 18hr fast 
and 120 minutes at 4°C 
 
 
  
xii
PREFACE 
 
Chapters II, IV, VI are all original unpublished works 
 
Sections from Chapter I were published in: 
Keeler AM, Flotte TR. Cell and Gene Therapy for Genetic Diseases: Inherited 
disorders affecting the lung and those mimicking SIDS.  Hum Gene Ther. 2012 
 
Sections from Chapter III and V were published in: 
Keeler AM, C.T., Walter G, Zeng H, Shaffer SA, Dungtao F, Erger K, Cossette T, 
Tang Q, Mueller C, Flotte TR. Long-term Correction of Very Long-chain Acyl-CoA 
Dehydrogenase Deficiency in Mice Using AAV9 Gene Therapy. Mol Ther, 2012. 
 
All qPCR from Chapter III, IV and V  was preformed by Conlon T and anaylized 
and prepared by Keeler A, with the exception of Figure 4.11 which was 
preformed/analyzed /prepared by Keeler A, also parallel qPCR of different short-
term data sets were preformed by A.Keeler in parallel but not presented here. 
 
All immunohistochemistry from Chapter III, IV and V was preformed by Dungtao 
F, but images were analyzed/perpared  by Keeler A. 
 
Confocal Microscopy, in Chapter IV, staining was done by Dungtao F, but all 
microscopy/ image analysis and preparation was done by Keeler A. 
 
All Magnetic Resonance Spectrometry from Chapter V was preformed/analyzed 
by Walter G and prepared by Keeler A. 
 
All other technigues described were performed by Keeler A, unless otherwise 
noted. 
 
Chapter VII was orginally published as: 
 
Mueller C, Braag SA, Keeler A, Hodges C, Drumm M, Flotte TR. Lack of cystic 
fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to 
aberrant cytokine secreation and hyperinflammatory adaptive immune responses. 
Am J Respir Cell Mol Biol, 2011.44(6):922-9  
 
Mueller C prepared: Figure 7.1& 2 
Keeler A prepared: Figure 7.4,5,6 
Mueller C and Keeler A prepared: Figure 7.3&7 
 
Original ideas: Mueller C and Flotte TR, except relating to Figure 7.4 Keeler A 
 
Manuscript was prepared by Mueller C and Flotte TR, except methods were 
Keeler A 
xiii
 
Manuscript has been modified for this work 
 
Chapter VIII was originally published as: 
Mueller C, Keeler A, Braag S, Menz T, Tang Q, Flotte TR. Modulation of 
exaggerated-IgE allergic responses by gene transger-mediated antagonism of IL-
13 and IL-17e. Mol Ther, 2010.18(3):511-8 
 
Mueller C prepared: Figure 8.2,3,5 
Keeler A prepared: Figure 8.1,6,7 (unpublished Figure 8.8) 
Menz T prepared: Figure 8.4, Table 8.1 
 
Original ideas: Mueller C and Flotte TR- receptor therapy, Keeler A- flow 
cytometry experiments relating to Figure 8.1,6,7,8 
 
Manuscript was prepared by Mueller C, Keeler A and Flotte TR 
 
Manuscript has been modified for this work 
 
  
 
1
CHAPTER I: Introduction to Mitochondrial Fatty Acid Oxidation 
and Defects in Mitochondrial Fatty Acid Oxidation 
   
Fatty-acid oxidation (FAO) is a cyclic process in which fatty acids are 
metabolized to produce energy.  FAO is also important in removing toxic 
accumulations of certain fatty acids, such as short branched-chain fatty acids 
created by degradation of branched-chain amino acids.  Under normal fed 
conditions, many organs preferentially derive their energy from glycolysis, but 
under certain conditions, such as fasting, exercise or metabolic stress, fatty-acid 
oxidation is an important source of energy. However, the heart’s preferred energy 
source, from which it derives 70-95% of its energy, is FAO(1, 2). Skeletal muscle 
during low-intensity prolonged exercise can get 60% of its energy from FAO(3). 
In utero a fetus receives a constant supply of glucose from the placenta, but after 
birth 60% of it calories consumed from breast milk are fat, so highly oxidative 
tissues must rely on FAO for energy(4). During periods of fasting, the liver uses 
FAO to produce acetyl-CoA, which are further processed to produce ketones.  
The ketones can then be used for energy in the brain where glucose is the 
preferred energy source.   
FAO can take place either in the mitochondria or in the peroxisomes, but 
generally peroxisomes only handle unusual fatty acid species and those 
containing chain-lengths larger than 20 carbons, which are shortened and 
oxidation is then finished in the mitochondria. Both α-oxidation and β-oxidation 
can occur in the peroxisomes but the mitochondria can only perform β-oxidation. 
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ω-oxidation occurs in the endoplasmic reticulum.  The focus of this chapter will 
be on mitochondrial β-oxidation and disorders of β-oxidation primarily acyl-CoA 
dehydrogenase deficiencies. 
In order for β-oxidation of fatty acids to occur, fatty acids must first be 
transported into the mitochondria as illustrated in Figure1.1. Free fatty acids are 
esterified with coenzyme-A to produce acyl-CoA’s inside the cytosol, which are 
the precursors for β-oxidation.  Long chain fatty acids, chain lengths of 12 
carbons or more, are believed to be actively transported into the mitochondrial 
membrane.  On the outer mitochondria membrane, carnitine 
palmitoyltransferase-1 (CPT-1) converts long chain acyl-CoA’s to acyl-carnitine, 
translocating them to the inner mitochondria membrane.  To cross the inner 
mitochondria membrane, carnitine acyl-carnitine translocase carries the acyl-
carnitines in exchange for free carnitine.  Finally carnitine palmitoyltransferase-2 
(CPT-2) converts them back to acyl-CoAs.  In order for FAO to occur 
transportation into the mitochondria is essential.  In the case of defects of β 
oxidation the transport system also works in reverse, except the fatty acids 
remain as acyl-carnitines in the cytosol where they transfuse out of the cell and 
into the blood (Figure1.1). 
Following mitochondrial transport, β oxidation occurs in the following four 
steps as illustrated in (Figure1.1): (1) dehydrogenation, in which acyl-CoA–
dehydrogenases (ACADs) catalyzes a double bond between C-2 and C-3 and 
are noncovalently bound to flavin adenine dinucleotide (FAD) to accept electrons, 
	   3	  
 
Figure 1.1 Transportation and Oxidation of Long Chain Fatty Acids in the 
Mitochondria 
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(2) hydration of the bond between C-2 and C-3 by enoyl CoA hydratase, which is 
stereospecific and forms only the L-isomer, (3) oxidation by L-β-hydroxyacyl-
CoA-dehydrogenase converting the hydro group to a keto group and using NAD+ 
as an electron acceptor, and (4) thiolysis by β-ketothiolase cleaving the thiol 
group of CoA using free CoA.  This results in an acetyl-CoA molecule and the 
acyl-CoA molecule that is two carbons shorter.  This spiral continues shortening 
the acyl-CoA molecule two carbons at a time ultimately producing two final 
acetyl-CoAs. Acetyl-CoA can then go to the Citric Acid cycle and electron 
transport chain and produce 10 ATPs.  Adding the additional electrons captured 
during step 1 and 3 of β-oxidation, more ATP is made from fatty acid oxidation 
than would be for the same carbon length glucose molecule. The electrons from 
the reduced FAD are removed from the ACADs by a mechanism, involving 
electron-transferring flavoprotein (ETF), which only recently has become better 
understood(5-7).  
Alternative forms of oxidation such as α-oxidation and ω-oxidation are 
necessary if carbon 3 has a functional group, such as a methyl group.  The rest 
of the introduction will focus on defects in mitochondrial fatty acid oxidation, and 
primarily acyl-CoA dehydrogenases. 
Acyl-CoA dehydrogenases (ACADs) are a family of flavoenzymes that are 
responsible for catalyzing α, β-dehydrogenation of acyl-CoA and using use ETF 
to transfer elections.  There are at least eleven known family members which 
function in either straight chain β-oxidation of fatty acids or metabolism of 
5
branched-chain amino acids. All ACADs are processed into the mature form in 
the mitochondria, but encoded in the nuclear genome and translated in the 
cytoplasm.  The enzymes involved in straight chain β-oxidation are: very long 
chain acyl-CoA dehydrogenase, (VLCAD), acyl-CoA dehydrogenase-9 (ACAD9), 
long chain acyl-CoA dehydrogenase (LCAD), medium chain acyl-CoA 
dehydrogenase (MCAD) and short chain acyl-CoA dehydrogenase (SCAD).  
They are responsible for catalyzing the first steps of mitochondrial fatty acid 
oxidation.  As their names suggest each enzyme has specificity for a particular 
chain length of fatty acid for example VLCAD towards palmitoyl-CoA (C16) 
making it the rate-limiting enzyme of long chain FAO.  All diseases of FAO 
described here are inherited recessive disorders caused by loss of protein 
function. 
VLCAD Deficiency 
VLCAD differs from the rest of the acyl-CoA’s, in that it is structurally 
active in homodimer form as opposed to homotetramer, and is associated with 
the inner mitochondrial membrane instead of found within the inner mitochondrial 
space. VLCAD can catabolize long chain fatty acids from 24-14 carbons in size 
but it has optimal specificity for chain lengths of C14-18(8).  The cavity depths of 
ACADs account for the specificity for particular chain lengths of acyl carnitine 
chains as well as VLCAD also has a binding pocket much wider then other 
ACADs.  The gene is approximately 5.4kb with 20 introns located on 
chromosome 17 between bands p11.2 and p11.13105. The resulting protein 
6
encoded is 67 kilodaltons in size.   Incidence of VLCAD disorder has been 
reported to be from 1:30,000 to 1:85,000 live births (9, 10).  
 
Disease Characteristics:   
ACADs are responsible for catalyzing the first step in FAO and VLCAD is 
the rate limiting ACAD; in the absence of functional VLCAD enzyme long chain 
fatty acids are accumulated and an energy deficiency is created.  There have 
been three phenotypes associated with VLCAD deficiency, which represent 
energy deficiencies in different highly metabolic organs.  Of the three 
phenotypes, the earliest onset is also the most severe.  It often presents as a 
cardiac phenotype, with cardiomyopathy as well as hepatomegaly, hypotonia and 
hypoglycemia within the first few months of life.  The second phenotype presents 
during childhood and is associated with a liver phenotype, characterized by 
reoccurring hypoketotic hypoglycemia.  The final phenotype is the most mild, 
occurring in late childhood/early adulthood as a mostly muscle phenotype 
presenting with rhabdomyolysis and myopathy. Since the establishment of better 
screening, patients with more severe phenotypes have increased lifespans 
surviving to adolescence, and are showing phenotypes of late onset disease 
such as exercise-induced rhabdomyolysis.  There has been a genotype-
phenotype correlation that has been recorded with VLCAD deficiency that is not 
detected with MCAD deficiency(11).  Null mutations are more likely to present 
with severe symptoms in early-childhood while patients with missense mutations 
7
present with milder phenotypes.  However since VLCAD does not have a 
predominating mutation, and many different mutations have been identified, 
some missense mutations have been associated with severe disease.  Residual 
enzyme activities of specific mutations have also been useful in predicting clinical 
outcomes.  Patients with less than 10% activity will develop clinical features in 
absence of treatment, and patients with less than 20% activity may also be at risk 
for serious clinical disease(12).   For example, one fatal case occurred in a 
patient with a genotype encoding a protein that retains residual activity. This 
mutation is often found in many asymptomatic patients(13).   Because VLCAD 
has over 80 different pathological mutations identified it is difficult to determine 
how all the mutants inhibit functional activity but most are thought to disrupt 
protein stability. 
 
Screening/Testing:   
As stated earlier, in patients with a metabolic block the transport of fatty 
acid accumulates, as acyl-carnitines, out of the mitochondria and into the blood 
occurs at a high frequency.  These acyl-carnitine species are readily detectable 
by tandem mass-spectrometry (MS/MS).  Screening by MS/MS for specific chain 
length accumulations provides clear evidence of a metabolic disorder; in the case 
of VLCAD, C14:1, C14:2, C14 and C12:1 chain lengths accumulate.  VLCAD 
screening has been added to the standard panel as part of the newborn 
screening program across all fifty states.  Prior to newborn screening up to 5% of 
8sudden infant death syndrome (SIDS) were likely caused by a disorder of 
FAO(14).  Accumulations of acyl-carnitines are measured from a dried blood spot 
taken shortly after birth. Confirmation can be made by analysis of VLCAD 
enzyme activity from various tissues as well as analysis of β-oxidation of 
fibroblasts. Since the advent of newborn screening, the prevalence of VLCAD 
deficiency has become higher than originally expected and many patients remain 
asymptomatic suggesting they would have gone undiagnosed prior to newborn 
screening. 
 
Management: 
 During periods of metabolic derangement patients are given IV glucose, 
often with insulin.  To prevent this metabolic status, patients are to avoid fasting, 
myocardial irritation, dehydration, high fat diets and anesthetics containing high 
doses of long chain fatty acids(15).  Patients with the severe forms of VLCAD 
deficiency are placed on medium-chain triglyceride (MCT) supplementation and 
often have nocturnal gastric drip feedings. Although MCT supplementation is 
considered safe, many question its usage and long-term effects. Uncooked 
cornstarch is often given as a source of sustained release glucose.   
 
Experimental Therapies: 
MCT supplementation: 
9Several clinical papers have cited severe VLCAD deficient patients’ 
reversal of cardiac symptoms after daily MCT supplementation, but long-term 
studies have not been done in humans(16, 17).  However, work published in 
mouse studies reveals that long-term supplementation with MCTs increases 
serum free fatty acids, shifts in body triglyceride storage, as well as fat 
accumulation and oxidative stress in the liver(18).  Spiekerkoetter and colleagues 
have published multiple mouse studies comparing different treatments of MCT in 
VLCAD deficient mouse models. They have demonstrated that MCT bolus prior 
to exercise did not cause steatosis or impaired lipid metabolism and decreased 
accumulates in skeletal muscle (19, 20).  MCT supplementation before exercise 
has had promising results in recent clinical studies as well.  Eleven patients who 
had long chain fatty acid oxidation disorders including: carnitine 
palmitoyltransferase-2 (CPT2) deficiency, long-chain 3-hydroxyacyl CoA 
dehydrogenase (LCHAD) deficiency and VLCAD deficiency, were given either 
isocaloric MCT or carbohydrate supplementation and then completed a 45 
minute treadmill workout.  At a different time, patients were given the other 
supplementation and the same exercise protocol was repeated.  Following MCT 
supplementation, patients demonstrated altered substrate oxidation, resulting in 
increases in ketones as well as a decreased heart rate (21). However another 
clinical exercise study saw no benefit to either IV glucose or MCT 
supplementation, in terms of exercise tolerance, in two VLCAD deficient patients 
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(22). No clinical studies have been performed evaluating the dose of MCTs or 
when dosing should occur (23). 
 
Carnitine supplementation: 
Clinical case reports have demonstrated clinical improvement in VLCAD 
deficient patients after starting carnitine supplementation.  In mouse models for 
VLCAD deficiency, studies looking at carnitine supplementation saw an increase 
of toxic acyl-carnitine accumulates in tissues without replenishment of free 
carnitine(24, 25).  Clinically, carnitine is often supplemented in addition to MCT. 
 
Triheptanoin: 
A clinical study was preformed first testing in vitro with VLCAD deficient 
fibroblasts and then in vivo with three patients with VLCAD deficiency for 
supplementation with odd chain fatty acids. The hypothesis was that by replacing 
medium even chain fatty acids with medium odd chain fatty acids, allowing 
production of both acetyl-CoA and anaplerotic propionyl-CoA, would result in 
improved cardiac and skeletal muscle function and energy production by allowing 
for replacement of catalytic intermediates of the citric acid cycle(26).   Odd chain 
fatty acids of different chain lengths (C15, C9 and C7) were tested in VLCAD 
deficient patient fibroblasts and heptanoate (C7) was found to be the best 
potential therapy as normal amounts of propionyl carnitine (C3) were produced 
without a significant accumulation of heptanoyl carnitine (C7).  Three patients 
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were switched from MCT therapy after three days of testing to triheptanoin. In 
comparison to MCT treatment, patients treated with triheptanoin produced both 
four and five carbon ketone bodies, not just four-carbon ketone bodies, and 
plasma heptanoate accumulates were no more than octanoate after MCT 
treatment.  Patients 1 and 2 were on the therapy for 26 months and 22 months 
respectively, and only patient 2 had one hospitalization for rhabdomyolysis after 
15 months on therapy.  Significant improvement was observed in muscle 
strength almost immediately after treatment as well as reduction of hepatomegaly 
and cardiomyopathy in all patients. 
 
Bezafibrate: 
Bezafibrate has only been tested so far in vitro for VLCAD deficiency, but 
is widely prescribed for hyperlipidemia. The hypothesized mechanism is that 
fibrates may stimulate FAO by being an agonist of peroxisome proliferator-
activated receptors (PPARs)(27). Increase of FAO capabilities of patient 
fibroblasts from myopathic forms of VLCAD deficiency, but not severe forms, was 
observed after exposure to bezafibrate.  Another study tested 33 different 
fibroblast cell lines, with 45 different mutations, from VLCAD patients and was 
able to show phenotypic correction of 21 different genotypes(28).  No difference 
was detected in VLCAD RNA expression between the 33 different phenotypes 
but in the 11 genotypes related to severe phenotypes little to no residual VLCAD 
activity was observed after treatment.  A pilot trial of bezafibrate was performed 
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in 6 patients with related CPT-1 and CPT-2 deficiency resulting in improvement 
of conditions with increased physical activity and decreased muscle pain(29). 
 
Dantrolene Sodium: 
The benefit of adjunctive muscular relaxant dantrolene sodium was shown 
in a clinical case in one VLCAD patient with recurrent rhabdomyolysis(30). 
 
Resveratrol: 
In a study using fibroblasts from mild forms of VLCAD and CPT-2 deficient 
patients, a dose and time dependent increase of FAO flux was demonstrated 
after resveratrol treatment, suggesting a possible therapy for mild forms of 
VLCAD and CPT-2(31). 
In conclusion, therapeutic options are very limited, including the current 
standard treatment of MCTs, as patients are still hospitalized with recurrent 
periods of hypoglycemia and rhabdomyolysis while taking MCTs and long-term 
effects have not been studied.  Most experimental therapies focus on 
augmenting VLCAD protein such as bezafibrate and resveratrol, which do not 
work for severe cases of VLCAD deficiency where better therapeutic options are 
needed most. 
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ACAD9 Deficiency 
ACAD9 has only recently been discovered with the gene identified in 
2002(32) and reports of patients with ACAD9 deficiency in 2007(33).  ACAD9 
has an overlapping specificity with VLCAD from metabolizing fatty acids of C14 
to C20, as well as sharing very similar sequence homology(34).  Interestingly, it 
also is a functional dimer much like VLCAD, but unlike other ACADS.  Unlike 
VLCAD, it is highly expressed in the brain with primarily neuronal expression(33).  
ACAD9 and VLCAD have similar expression levels in the liver, but the muscle is 
dominated by VLCAD expression.  The role of mitochondrial β-oxidation in the 
human CNS is controversial as neurological problems are usually not present in 
patients with these ACAD deficiencies.  However, of the three patients reported 
with ACAD9 deficiency all had neuronal abnormalities such as moderate to 
severe reduction of neurons in the neocortex, cerebellum and hippocampus(33).  
It has been suggested that ACAD9 plays a role in oxidative phosphorylation, and 
mutations in ACAD9 could be responsible for some causes of mitochondrial 
complex I deficiency which is linked to many neurological diseases(35, 36). 
 
LCAD 
No cases of LCAD deficiency have been reported in humans, and patients 
originally diagnosed with LCAD deficiency were found to have VLCAD deficiency 
after the VLCAD protein was discovered in 1992. In vitro, LCAD’s activity ranges 
from C20-C6 with optimal activity at C12(8).  Therefore VLCAD and LCAD would 
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have an overlapping specificity for certain lengths of long chain fatty acids.  
However, in vivo activity for LCAD shows specificity for branched chain fatty acid 
oxidation.  Also unlike VLCAD and MCAD, which are highly expressed in liver, 
heart and skeletal muscle, LCAD’s mRNA and protein expression is very low in 
these highly metabolic tissues in humans(37, 38).  Interestingly in rodent models 
LCAD is highly expressed within these tissues, and LCAD deficient mice have a 
more severe phenotype than VLCAD deficient mice(37). 
 
 
MCAD Deficiency 
MCAD deficiency is the most common disorder of fatty acid oxidation with 
a disease frequency of approximately 1:10,000 (39).  The human MCAD gene is 
44kb long located on chromosome 1.  A 421 amino acid precursor protein is 
encoded which is responsible for importation into the mitochondria, protein 
folding and assembly into the mature homotetramer form. It catalyzes fatty acids 
from C12-C4, with an optimal activity at C8.  In MCAD deficiency, the most 
common mutation is a guanine instead of an adenine at position 985 (985A/G) 
which caused a lysine to be translated instead of glutamic acid at position 304 
(K304E).  It has been reported that at least 90% of patients are at least 
heterozygous for this mutation and 80% of those patients are homozygous for 
the K304E mutation(40).  Newborn screening has revealed more information on 
less common mutations and now more than 54 variants of MCAD deficiency 
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have been characterized(40).  Interestingly, MCAD has a clinically variable 
phenotype like VLCAD even though it has a relatively homozygous genotype 
unlike VLCAD.  It is possible that environmental and epigenetic factors play a 
role in clinical outcomes, as patients carrying the K304E mutation, which is 
considered a severe mutation can remain asymptomatic(41).  A mild phenotype 
of MCAD has emerged since newborn screening, which generally correlates to a 
heterozygous K304E mutation or two non-K304E mutations.  However, patients 
with less severe mutations with high residual activity have still developed 
hypoglycemia and become comatose during metabolic decomposition and 
should still be considered at risk for clinical manifestations(42-44).  
 
Disease Characteristics:   
MCAD is regarded as mild in comparison to VLCAD deficiency, however 
in undiagnosed patients 25% die suddenly with the first presentation of disease.  
Of the survivors 30-40% show developmental delay and irreversible neurological 
impairment(45).  Even with the early asymptomatic detection through newborn 
screening, deaths have been reported in MCAD patients and at least 20 patients 
who had previous clinical knowledge of the disorder have died suddenly(46).  
Patients usually present between three and 24 months, but adult presentations 
are possible and can result in sudden death(47, 48). The most common 
presenting symptom is hypoglycemia, often in combination with hypoketosis, 
hepatomegaly, hyperuricemia and elevated liver transaminases.  Autopsies after 
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patient sudden death reveal cerebral edema, and fatty infiltrates in liver, kidneys 
and heart(49).  In long-term studies, patients complain of fatigue, muscle pain 
and exercise intolerance(50). 
 
Screening:  
MCAD is part of the standard newborn screening program in all 50 states.  
MCAD is diagnosed by plasma accumulations of C6-C10, or accumulations in 
urine organic acids or acylglycines.  Confirmation can be determined by fatty acid 
oxidation or MCAD enzyme activity in fibroblasts as well as molecular genetic 
testing.  
 
Management:   
During disease manifestations, simple carbohydrates or IV infusion of 
glucose may be necessary.  Treatment for MCAD is mostly avoidance of fasting, 
and a relatively low fat diet.  Uncooked cornstarch is often given at night for 
overnight glucose supply during infancy.  Supplemental L-carnitine is still being 
evaluated for its clinical significance. 
 
SCAD Deficiency 
SCAD is the last enzyme in the acyl-CoA dehydrogenase cycle, and unlike 
the other disorders results in almost normal amounts of acetyl-CoA. Its 
prevalence has been found to be 1:50,000 in the Netherlands(51). It catalyzes 
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fatty acyl chain lengths from C4. It is caused usually by missense mutations that 
disrupt proper protein folding(52).  There are two susceptibility missense variants 
often associated with SCAD, 511C>T and 625G>A.  Compound heterozygosity 
with a severe mutation is likely to produce an SCAD deficiency.  Biallelic 
susceptibility variants may also cause a clinical phenotype, but is generally 
thought not to be a significant risk due to how common the variants are within the 
general population. 
 
Disease Characteristics:   
Unlike VLCAD and MCAD, sufficient energy can be produced from the 
preceding steps of fatty acid oxidation. Hypoglycemia is rare in SCAD patients 
and they generally have normal ketogenesis(53, 54).The accumulation of butyric 
acid (C4) and its derivatives are not toxic to the heart and liver. However 
neurological symptoms of SCAD can be attributed to butyric acid and its 
derivatives, mainly ethylmalonic acid, accumulating within the central nervous 
system.  Almost all patients present with clinical symptoms in early life, generally 
before the age of five.  SCAD has an extremely broad clinical phenotype with 
many patients remaining normal while others show severe symptoms including 
dysmorphic facial features, failure to thrive, metabolic acidosis, ketotic 
hypoglycemia, lethargy, developmental delay, seizures, hypotonia, dystonia and 
myopathy(55).  In the largest study to date of 114 patients, three groups emerged 
encompassing most of the patients with: 30% presenting with developmental 
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delay and hypotonia without seizures, 25% with developmental delay and 
seizures and 20% with failure to thrive and hypotonia(56).  Overlapping 
phenotypes of failure to thrive, developmental delay and hypotonia were 
observed in 14% of patients.  The remaining patients either had a mixture of 
symptoms including dysmorphic features, cardiomyopathy, myopathy and 
hepatic steatosis (7%) or remained asymptomatic (4%).  However, symptoms 
often disappear after initial diagnosis and can often be explained by other 
causes.   
 
Testing/Screening:   
SCAD is not specifically tested for by the state of Massachusetts as part of 
the newborn screening process, but through testing for VLCAD and MCAD, 
which are mandated, patients who potentially have SCAD are potentially 
recognizable. SCAD deficient patients have elevated levels of butyryl carinitine 
(C4) in blood or plasma spots or increased concentrations of ethylmalonic acid in 
their urine. SCAD deficient patients may have either a mutation/mutation or 
mutation/susceptibility variant or variant/variant in both ACADS alleles(51).   
SCAD enzyme levels are not clinically helpful, but skin fibroblast fatty acid 
oxidation studies can reflect enzyme levels and can confirm diagnosis(57). 
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Management:   
The need for treatment of these patients is unclear because most patients 
are asymptomatic when healthy.  However, like VLCAD and MCAD, prevention 
of symptoms is maintained by avoidance of fasting.  There are no accepted 
recommendations as far as dietary manipulations. During periods of metabolic 
acidosis, or hypoglycemia, which is uncommon in SCAD, treatment is similar to 
other disorders of fatty acid oxidation with intravenous fluids therapy of high 
dextrose solutions to promote anabolism. Supplementation of riboflavin has been 
suggested as a possible therapy as it is the precursor to flavin adenine 
dinucleotide (FAD) which is an essential cofactor for SCAD(58). 
 
Other disorders of Fatty Acid Oxidation 
With 21 genes encoding at least 17 different enzymes for mitochondrial β 
oxidation, mutations in most genes associated with mitochondrial β oxidation 
correlate with human disease(4).  There are also diseases associated with 
peroxisomal oxidation, however symptoms originate more from toxic 
accumulations than from energy deficiencies.  Here the focus is on four disorders 
that have similar presentations and symptoms to acyl-CoA dehydrogenase 
deficiencies, particularly VLCAD, two also involved in oxidation of long chain fatty 
acids and two involved in transportation into the mitochondria. 
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CPTI: 
Carnitine palmitoyltransferase-1, the enzyme responsible for bringing 
long-chain fatty acids into the mitochondria, is made by three distinct genes to 
produce a CPT-1a liver isoform, CPT-1b skeletal/cardiac muscle isoform and 
CPT-1c brain isoform.  Only CPT-1a has been associated with human disease, 
with patients presenting with hypoketotic hypoglycemia, but with little to no 
cardiac or skeletal involvement as CPT-1b is the predominant isoform in 
skeletal/cardiac tissue.  CPT-1a and CPT-1b knock-out mice are embryonic 
lethal, interestingly the CPT-1c brain isoform is viable and its function is not well 
understood as it does not possess palmitoyltransferase activity(59). 
 
CPTII: 
CPTII is responsible for converting the long chain fatty acid back to the 
acyl-CoA form during transport into the inner membrane of the mitochondria.  
Patients deficient in this enzyme have very similar phenotypes to VLCAD 
deficient patients with the most severe forms presenting at infancy with 
hypoketotic hypoglycemia, cardiomyopathy and sudden death.  Patients with 
adolescent to adult presentation have exercise-induced pain and weakness and 
myoglobinuria. 
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mTFP and LCHAD: 
The mitochondrial trifunctional protein (mTFP), consists of 4 α subunits 
and 4 β subunits and carries out steps 2-4 of FAO for long chain fatty acids.  The 
α units are responsible for steps 2 and 3 and the β for step 4. LCHAD, long chain 
3-hydroxyacyl-CoA dehydrogenase, activity is contained in the α subunit, and 
mutations within this result in hypoketotic hypoglycemia.  Mutations can also 
affect all three enzymatic activities, mTFP deficiency, and result in 
cardiomyopathy.  Interestingly mTFP and LCHAD deficiency present with two 
additional phenotypes not associated with other defects in long-chain fatty acid 
metabolism.  In mTFP patients, 80% present with neuropathy, but only 5-10% of 
patients with LCHAD(60, 61).  Conversely, 30-50% of LCHAD patients present 
with retinopathy, whereas only 5-13% of mTFP patients have retinopathy(60-63).  
Neuropathy and retinopathy are not generally associated with the other disorders 
of long chain fatty acid oxidation. 
 
In summary, mitochondrial FAO has an essential function in energy 
production, especially in highly metabolic organs such as the liver, heart and 
skeletal muscle, as well as in degrading toxic accumulates.  There are multiple 
disorders associated with mitochondrial FAO that are clinically important and 
most are detected as part of the Newborn Screening program.  To date no 
definitive therapy exists for these diseases. 
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CHAPTER II: Gene Therapy for Beta-Oxidation Disorders 
Gene Therapy 
In principle, using a genetic therapy to correct a single gene disorder is 
very simple.  Augmentation of protein expression for autosomal recessive 
disorders caused by loss of function or silencing protein expression for dominant 
disorders caused by gain of function can provide therapies for a multitude of 
diseases.  However the technological hurdles associated with the practical 
correction of these diseases are intrinsically more challenging.  Safety as well as 
efficiency must be evaluated; while a given vector may excel in one aspect it may 
also disappoint in another. 
The first hurdle to overcome is the vector’s ability to transport the genetic 
material into the targeted cells. Either cells can be removed and the therapy can 
be preformed ex vivo, or the targeted cells can be treated in vivo. Several 
methods have been proposed, for in vivo gene transfer including: plasmids, viral 
vectors, and liposomes.   
Among viral vectors, adeno associated virus (AAV) has stood out in terms 
of both efficiency and safety.  AAV, was originally discovered as a contaminant of 
Adenovirus preparations, which is where it derives its name but is not related 
genetically to Adenovirus.  It is a member of the parvovirus family of the genus 
dependovirus, and as its name suggests it is replication deficient depending on 
other viral genes in order to replicate.  Because of this natural life cycle, AAV 
remains latent in infected cells predominantly in extra chromosomal concatemers 
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until provided with proteins for replication by another virus such as adeno or 
herpes virus(64, 65).  AAV is associated with no known human disease, and 
many of the serotypes are widespread throughout the human population, with up 
to 90% of the adult humans seropositive for at least one known serotype(66).  
These innate wtAAV viral attributes allow for AAV to be a safe and efficient viral 
vector in vivo. 
 
AAV Virology 
The 4.7kb single stranded DNA viral genome is very simple in structure, 
consisting of two open reading frames, rep and cap and two non-coding 145 
nucleotide inverted terminal repeat (ITR) sequences at the 5’ and 3’ end(67, 68).  
The rep gene is transcribed from two different promoters to allow for production 
of 4 Rep proteins.  The cap gene is transcribed from one promoter to produce a 
total of three proteins through alternative splicing and a non-canonical ACG start 
codon.  The capsid structure is T=1 icosahedral particle, with a total of 60 copies 
of the three viral proteins at a ratio of 1:1:8 of VP1:VP2:VP3.  Recently another 
protein was found to be encoded within the cap gene responsible for trafficking 
cap proteins to the nucleolus for assembly as well as playing a role in viral 
assembly(69). 
Over 100 novel serotypes have been discovered largely by Gao and 
Wilson(70), at least ten have been well classified.  Although differing AAV’s are 
commonly referred to as “serotypes” they are not true serotypes in that they are 
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not immunologically distinguished.  AAVs are now classified using HIV taxonomy 
to segregate AAV into six “clades” based on sequence diversity so that they 
share overall structure, serology and functional aspects(70-72). 
AAV enters the cell through receptor-mediated endocytosis, allowing for 
cellular specificity.  Different AAV serotypes have been associated with different 
receptors: AAV1 binding α2-3- and α2-6-N-linked sialic acid(73-75), AAV2&3 
binding heparin sulfate proteoglycan receptor, with a co-receptor of either 
fibroblast growth factor receptor or αv-β5 integrin(76-79), AAV4 binding α2-3-O-
linked sialic acids(80), AAV5 binding α2-3N linked sialic acid with platelet derived 
growth factor receptor(73, 80, 81), AAV6 binding both heparin sulfate 
proteoglycan and sialic acid(75, 82), and AAV8&9 associated with the 
widespread laminin receptor but the primary receptor for AAV9 is N-linked 
galactose (83, 84). The varied AAV serotype receptor specificities allow for 
differing tropism between cell types and within different organisms. 
 
AAV Gene Therapy 
To construct recombinant AAV (rAAV) vectors all viral coding regions are 
deleted and only the ITRs are retained for packaging.  Rep and cap genes are 
provided in trans as well as additional adenoviral helper genes.  Often viruses 
are transcapsidated by using the AAV2 ITRs but differing capsid sequences as 
they determine tropism, and packaged using AAV2 rep gene.  Additional vector 
manipulation has allowed for normal single stranded AAV (ssAAV) genome to be 
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converted into a transcriptionally-active self complementary double stranded 
genome (scAAV) by mutations in the ITRs(85).  Although packaging capacity is 
halved, these vectors have been shown to be more efficient since they skip the 
rate-limiting steps of transduction of either second-strand synthesis or opposite 
strand self-annealing(86, 87). 
By using different capsid genes, rAAV’s can be targeted to specific tissues 
for different therapeutic effects.  The route of administration also plays a role in 
efficiently targeting specific tissues. rAAV9 has been found to have a very broad 
distribution when injected intravenously showing expression in tissues such as 
the liver, heart, muscle, brain, and lung in rodents with more robust expression 
than many other vectors(88, 89).  rAAV9 has also shown robust expression when 
injected locally, whether in the eye by subretinal injection(90) or brain by 
intracranial injection(91).  Modifications have also been made to enhance tissue 
transduction of rAAV vectors. Specific tyrosines in the AAV capsid have been 
identified which can be phosphorylated causing impaired transduction and 
trafficking, however making point mutations to these tyrosines allows for high 
efficiency transduction by avoiding ubiquitination and proteasome-mediated 
degradation(92).  By avoiding proteasome degradation these vectors are also 
less immunogenic. 
Because some AAV’s such as AAV9, have broad transductions, 
modifications have been made to rAAV vectors to be more tissue specific.  The 
modifications can be split into two groups: modifying the capsid to change the 
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tissue tropism or modifying the genome sequence to limit expression in certain 
tissues.  One method of changing the capsids specificity is by inserting peptide 
ligand sequences into the capsid(93, 94).   DNA shuffling from multiple serotypes 
has also been used to alter tropism(95-97).  In addition, specific mutations can 
be made to the capsid structure, primarily at known receptors or co-receptors, to 
alter viral tropism(98).  In order to change the expression of the transgene rather 
than the viral tropism two different strategies have been employed.  One strategy 
involves using tissue specific promoters to drive expression in only the target 
tissues. The other strategy, uses RNAi to de-target expression in unwanted 
tissues.   Xie et al. put microRNA binding sites for miR-122, which has high 
prevalence in the liver, and miR-1, which has high prevalence in the heart and 
skeletal muscle, within the 3’ untranslated region of their reporter gene to 
downregulate expression in the liver, heart and skeletal muscle, in order to get 
more specific CNS expression(99).  Future directions for further specificity in 
targeted tissue transduction can be foreseen by combining techniques for a more 
tropic virus as well as specific promoter targeting and RNAi de-targeting within 
the same vector, or by combining multiple vectors. 
 
AAV Gene Therapy Trials 
rAAV vectors were first approved in 1994 for airway delivery in a human 
trial for cystic fibrosis, which subsequently began in November 1995(100).  This 
study progressed to enroll over 100 patients and went on to a Phase 2b.  The 
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first published trials, were for hepatic and intramuscular delivery of Factor IX in 
Hemophilia B patients(100). The hepatic delivery however was hampered by 
transient increase in hepatocellular enzymes and an immune response resulting 
in loss of expression(101). Immune responses have been detected against either 
the capsid or the transgene, but they are not always associated with clearance of 
expression(102).  A Phase 2 trial for α-1-Antitrypsin deficiency has had promising 
results in spite of inflammatory infiltrates, although therapeutic levels of protein 
have not yet been reached(103). In all, over 25 different clinical trials have been 
approved treating over 13 different disease including Parkinson’s disease, 
Canavan’s disease, α-1-Antitrypsin deficiency, muscular dystrophies and retinal 
degeneration(100).  Differing routes such as intracranial, intracardiac and 
intraocular administration, and differing serotypes AAV1, 2, 5 and 6 have all been 
approved.  
 
Gene Therapy for Disorders of Fatty Acid Oxidation 
In 1997, Kelly et al. created a liver specific SCAD knock-in by 
microinjection of SCAD-minigene within the SCAD deficient mouse model.  They 
were able to observe decreased lipid accumulates in the liver by oil-red-o 
staining and systemic correction of decreased accumulation of butyryl carnitine in 
the urine(104).  These studies provided a foundation that gene therapy through 
specific tissue targeting is possible for disorders of fatty oxidation, and also 
detected overexpression of the therapeutic protein was not detrimental. Holm et 
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al. next observed gene transfer to livers of SCAD deficient mice by hydrodynamic 
transfer(105). Although gene transfer occurred and 5% of liver cells expressed 
functional SCAD proteins 31 days post injection, systemic correction by reduced 
blood butryrl carnitine after fasting was not detected.  Conlon et al. published on 
gene therapy for SCAD disorder using intramuscular injection of rAAV1 and 
rAAV2 encoding SCAD providing both correction in vitro of SCAD deficient 
patient cells and in vivo in SCAD deficient mice(106). This targeted muscle gene 
therapy showed systemic correction of serum butyryl carnitine levels after fasting, 
using rAAV1 ten weeks post injection.  Also, a method of detecting lipid 
accumulates within specific tissues non-invasively in vivo was validated using 
Magnetic Resonance Spectrometry (MRS).   Next Beattie et al. used a liver 
directed approach, like Kelly et al, but using rAAV5 and rAAV8 for gene therapy 
in the SCAD deficient mouse(107). Using portal vein injections of rAAV8, protein 
expression was targeted to the liver where a decrease in lipid accumulates was 
observed by both oil-red-o staining and MRS 10 weeks post injection. Systemic 
correction was also observed by reduction of serum butyryl carnitines after 
fasting. 
In vitro correction of MCAD deficiency using a recombinant adenoviral 
vector has been performed but so far no gene therapy in vivo has been published 
for MCAD deficiency.  MCAD deficient human fibroblasts were infected with 
recombinant adenoviral vectors encoding MCAD, and whole cell medium showed 
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reduction of C6, C8 and C10(108).  These results are promising for future studies 
of an in vivo MCAD gene therapy. 
Although there is no known disease caused by LCAD deficiency in 
humans, an LCAD deficient mouse model exists.  Unlike humans, mice express 
LCAD at high levels in metabolically active tissues such as liver, skeletal and 
cardiac muscle(37, 38). The LCAD mouse model has a more severe phenotype 
then VLCAD mice, which mimics the severe clinical phenotype of VLCAD 
deficient patients(109).  Correction of LCAD +/- mice, which display an 
intermediate phenotype, was shown by both a muscle-targeted, rAAV1 injected 
intramuscularly, and a liver-targeted, rAAV8 through the portal vein, 
approach(110).  Reduction of the lipid peak by MRS was observed in the muscle 
10 weeks after intramuscular injection or rAAV1 as well as a systemic effect on 
decreased macrosteatosis in the liver by oil-red-o staining in female mice.  
Muscle-targeted transduction however was not able to reduce acyl-carnitine 
accumulates in the serum.  Reduction of both macrosteatosis and microsteatosis 
was observed by oil-red-o staining after portal vein injection of rAAV8. 
Hydrodynamic injection of VLCAD into VLCAD deficient mice was able to 
show expression of functional VLCAD protein, as well as correction in vitro 
observed in human VLCAD deficient fibroblast cells by reduction of acyl-carnitine 
accumulates(111). rAAV8 gene therapy using the CMV promoter delivered by 
systemic tail vein injection, was published by the same group (112).  Expression 
was shown in the liver of these mice at an early time-point, 11 days post-
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injection, but was not detected at a later time-point of 102 days post-injection, 
although vector genomes were still present.  Expression of VLCAD in the heart 
increased between 11 and 102 days, but muscle transduction was generally 
poor.  Correction of acyl-carnitine accumulations in the blood was observed 
throughout the study as well as fasting induced hypoglycemia.  Based on the 
previous work, we hypothesized that we could obtain correction of clinically 
relevant phenotypes of VLCAD deficiency in VLCAD deficient mice if we had 
long-term expression of VLCAD protein in the liver, cardiac and skeletal muscle 
by systemic injection of rAAV9 expressing VLCAD protein driven by a 
cytomegalovirus enhancer/chicken β-actin promoter (CBA) promoter. The 
following chapters will discuss this study of long-term expression of VLCAD 
protein after systemic injection of rAAV9-VLCAD(113). As well as addressing the 
important expression of VLCAD also observed in the brain after systemic 
injection suggesting that rAAV9-VLCAD crossed the blood brain barrier. 
Systemic correction was observed in reduction of blood acyl-carnitine 
accumulates, but tissue specific accumulates were measured in the liver, heart 
and muscle ex vivo, and in the liver and muscle in vivo by MRS. For the first time, 
correction of disease specific phenotypes, such as cold intolerance, induced 
hypoglycemia and hypotonia, were observed in animals receiving rAAV9- 
expressing VLCAD.  This study shows significant proof-of-principle for gene 
therapy to correct VLCAD deficiency, and taken together these studies have 
important clinical applications for diseases of mitochondrial fatty acid oxidation. 
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Chapter III: Gene Therapy for VLCAD- Transduction and 
Expression 
Introduction 
A large number of different serotypes of AAV have recently been 
discovered(71), and each have unique properties, giving gene therapists a 
diverse toolbox from which to chose their vectors. VLCAD deficiency presents 
with different phenotypes each relating to highly metabolic tissues:  a severe 
heart phenotype presents early in life with cardiomyopathy, a liver phenotype 
characterized by hypoketotic hypoglycemia, and a muscle phenotype 
characterized by rhabdomyolysis and exercised-induced muscle pain and 
intolerance.  Some patients experience symptoms from multiple phenotypes and 
as patients age they often shift from early onset heart and liver phenotypes to the 
muscle phenotype(114).  
In the previous attempt using gene therapy for treatment of VLCAD 
deficiency, rAAV8 serotype was used(112).  VLCAD expression was not detected 
long-term in the liver, nor was VLCAD protein highly expressed in the muscle. In 
order to target each tissue associated with disease in VLCAD, long-term and 
efficient expression must be achieved in the liver, cardiac and skeletal muscle. 
This treatment could effectively treat all phenotypes of VLCAD deficiency, as well 
as phenotypes that would develop with age.  rAAV8 is usually associated with 
long-term transduction of the liver, however in the previous study the 
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cytomegalovirus (CMV) promoter was used, which is known to be turned off in 
the liver(115).  In this study rAAV9 was used as it efficiently targets the liver, 
cardiac and skeletal muscle(89, 116), along with the hybrid chicken beta actin 
(CB) promoter, which does not get shutdown in the liver. Using these tools we 
hypothesize that long-term expression of VLCAD will be observed in the liver, 
cardiac and skeletal muscle, which will in turn provide therapeutic benefit to all 
tissues associated with VLCAD deficient phenotypes. 
Methods 
Animals: 
VLCAD -/- mice were created by Exil et al. and purchased from Mutant 
Mouse Regional Resource Centers (MMRC, University of Missouri, MO).  
VLCAD-/- animals were created by breeding VLCAD-/+ animals producing 
VLCAD-/- and VLCAD+/+ littermate controls, as well as VLCAD-/+ for future 
breeding. Mice were maintained in a pathogen-free facility with 12hr light and 
dark schedule.  Mice were fed PicoLab Mouse Diet 20 5058 (LabDiet, Richmond 
IN) until two weeks post-injection and then were placed on a standard chow.  
Mice received both diets and water ad libitum.   
All animal procedures were approved by University of Massachusetts 
Medical School Institutional Animal Care and Use Committee as well as 
University of Florida Institutional Animal Care and Use Committee in accordance 
with the Association for Assessment and Accreditation of Laboratory Animal Care 
International specifications.   
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rAAV vectors: 
rAAV2/9 pseudotyped vectors were generated to express human VLCAD 
under the transcriptional control of the cytomegalovirus enhancer/chicken β-actin 
promoter (CBA) (115).  rAAV vectors were produced, purified and tittered as 
previously described (UMMS Gene Therapy Center, Worcester MA)(117). 
 
Genomic DNA extraction and Quantitative PCR: 
DNA was extracted and quantified as previously described(118). Animals 
were sacrificed at indicated time points and tissues were harvested in a manner 
to avoid cross-contamination, snap frozen in liquid nitrogen and stored at -80°C.  
Genomic DNA (gDNA) was extracted using a DNeasy blood and tissue kit 
(Qiagen Inc., Valencia, CA, USA) according to the manufacturer’s instructions. 
gDNA concentrations were determined using an Eppendorf Biophotometer 
(Eppendorf, Hamburg, Germany). 
 rAAV genome copies in the gDNA from heart, liver, tibialis anterior (TA) 
muscle, gonands, lung, spleen, lymph nodes, brain and brown fat were quantified 
by qPCR with an ABI 7900 HT sequence detection system (Applied Biosystems, 
Carlsbad, CA, USA) according to the manufacturer’s instructions and results 
were analyzed using SDS 2.3 software.  Briefly, primers and probe were 
designed to amplify SV40 poly-A tail of the rAAV9-CBA-VLCAD vector.  A 
standard curve was generated using plasmid DNA containing the same SV40 
poly-A target sequence.  PCR reactions contained a total volume of 100µL and 
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were run at the following conditions: 50°C for 2 minutes, 95°C for 10 minutes, 
and 45 cycles of 95°C for 15 seconds and 60°C for one minute. 
DNA samples were assayed in triplicate.  In order to assay PCR inhibition, 
the third replicate was spiked with plasmid DNA at a ratio of 100-copies/µg 
gDNA.  If this replicate was greater than 40-copies/µg gDNA then the results 
were considered acceptable.  If a sample contained greater than or equal to 100-
copies/µg gDNA it was considered positive for vector genomes.  If a sample 
contained less than 100 copies/µg gDNA it was considered negative for vector 
genomes.  If less than 1µg of gDNA was analyzed to avoid PCR inhibition, the 
vector copy number reported was normalized per µg gDNA and the plasmid 
spike in was reduced to maintain the ratio of 100-copies/µg gDNA. 
 
Immunohistochemistry: 
Tissues were fixed in 10% neutral buffered formalin, and embedded in 
paraffin.  Immunohistochemistry was carried out by the Molecular Pathology and 
Immunology Core at University of Florida using the DAKO Autostainer plus 
protocol.  Briefly, 4 µm serial sections were removed of paraffin and incubated 
with 3% H2O2 in methanol to block endogenous peroxidase activity. Sections 
were treated with Trilogy (Cell Marque, Rocklin, California) at 950 C for 25 
minutes and blocked with Sniper (Biocare Medical, Walnut Creek, CA) to reduce 
non-specific background staining.  Sections were incubated with rabbit anti-
mouse VLCAD at room temperature for 1 hour. Then sections were incubated 
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with Mach2 Gt x Rb HRP polymer (Biocare Medical, Walnut Creek, CA) for 30 
minutes. Staining was visualized with DAB chromagen (Biocare Medical, Walnut 
Creek, CA). 
Results 
To assess the transduction and expression of rAAV9-VLCAD cDNA 
delivery, 6-8 week-old male VLCAD-/- or VLCAD+/+ littermate controls were 
injected into the tail vein with either rAAV9-CBA-VLCAD (1x1012vg) as a 
therapeutic agent or rAAV9-CBA GFP or PBS as controls.  Quantitative real-time 
PCR was performed on gDNA isolated from multiple tissues at 22-26 weeks post 
injection to determine tissue distribution of vector genomes (Fig. 3.1).  All tissues 
were negative for vector genomes in PBS VLCAD-/- or PBS VLCAD+/+ controls.  
In mice injected with rAAV9-VLCAD, the highest vector genome concentration in 
tissues associated with fatty acid oxidation, was observed in the liver followed by 
heart, skeletal muscle and brown fat. Expression is shown by hVLCAD antibody 
staining of the liver, heart, TA muscle and brown fat (Fig. 3.2a-h).  Also vector 
genomes were found present in tissues not associated with fatty acid oxidation 
including gonads, lung, spleen and lymph nodes (Fig. 3.1). Surprisingly a large 
amount of vector genomes were found in the brain, which will be discussed in 
depth in Chapter 4 (Fig 3.1).  Although transduction of the liver had the highest 
transduction among the tissues, liver expression was not widespread, with 
numerous cells expressing VLCAD at high levels while others did not express  
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Figure 3.1 Transduction of rAAV9-VLCAD 
Quantitative PCR of vector genomes. Means of 3 separate assays± SEM (error 
bars) are shown for each organ. n=7 for VLCAD-/- PBS Control, 6 for VLCAD-/- 
rAAV9-VLCAD treated and VLCAD +/+ PBS Control.  Only VLCAD-/- rAAV9 
treated are shown, as PBS Controls were all negative.  
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Figure 3.2 Expression of rAAV9-VLCAD 
 
Representative images at 5x magnification of VLCAD antibody staining in 
VLCAD-/- mice, sacrificed at range between 21-26 weeks post injection.  The 
tissues are labeled as follows: (a) Liver PBS Control (b) Liver, rAAV9-VLCAD 
treated (c) Heart, PBS Control (d) Heart, rAAV9-VLCAD treated (e) Tibialis 
anterior (TA) muscle, PBS Control  (f) TA, rAAV9-VLCAD treated (g) Brown fat, 
PBS Control and  (h) Brown fat, rAAV9-VLCAD treated. 
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VLCAD, which may be related to the perivascular (Fig. 3.2 b). Expression of 
VLCAD in the heart and TA was widespread (Figs. 3.2d, f).  Interestingly, 
transduction and expression was detected in the brown fat (Figs. 3.2h). 
Liver and muscle were also stained with hematoxylin and eosin and 
scored by pathologist, who was blinded to the treatment groups, for inflammation 
as well as macrosteatosis and microsteatosis (Fig 3.3).   Some inflammation in 
the liver was observed across all groups but no significant difference was 
observed in inflammation between AAV9-VLCAD treated VLCAD-/- mice or PBS 
controls. Surprisingly, low levels of portal vein inflammation and macrosteatosis 
were observed in VLCAD+/+ PBS animals that were not observed in the treated 
or untreated VLCAD-/- animals. No inflammation was detected in any group 
within the muscle.  Taken together, these results indicate that rAAV9-VLCAD 
vectors were able to sufficiently transduce and express for over 6 months in vital 
organs, which rely on fatty acid oxidation. 
However, female VLCAD-/- mice injected with the same vector, rAAV9-
CB-VLCAD, at the same dose 1x1012vg did not display the same expression 
patterns as the male mice.  In Figure 3.4, it is apparent that expression within the 
liver is markedly reduced, with little to no expression, the converse of what is 
observed in male mice.  This finding is not surprising, as it has been previously 
published that in mice AAV transduction in the liver is testosterone 
dependent(119).   Expression within other tissues, such as the heart and muscle, 
seem not to be affected and is similar to expression in male mice(Figure 3.4). 
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Figure 3.3: Inflammation of Liver Post-injection 
Liver sections from 22-26 weeks post injection were stained with hematoxylin 
and eosin and scored on a 0-4 scale, with 4 being the most severe inflammation, 
by a blinded pathologist for (a) parenchymal inflammation (b) portal inflammation 
(c) macrosteatosis (lipid vesicles that distort the nucleus) and (d) microsteatosis 
(lipid vesicles present but do not distort the nucleus).  N=7 for VLCAD-/- PBS 
Control and n=6 for both AAV9 treated and VLCAD+/+ PBS Control. 
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Figure 3-3: Inflammation of Liver Post-injection 
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Figure 3.4 Expression differences of rAAV9-VLCAD in Male and Female 
mice 
Representative images at 4x magnification of VLCAD antibody staining in male 
and female mice VLCAD-/- mice 12 weeks post injection of rAAV9-VLCAD. 
Panels a-d represent female mice: (a) Liver (b) Heart (c) Muscle (d) Brown Fat.   
Panels e-f represent male mice: (e) Liver (f) Heart (g) Muscle (h) Brown Fat. 
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Discussion 
Unlike the previous work by Merritt and colleagues(112), we were able to 
show long-term expression of VLCAD in all targeted tissues including liver, brown 
fat, cardiac and skeletal muscle.  The difference in long-term expression in the 
liver could have been due to the use of the CBA expression cassette over the 
CMV promoter, the latter of which is known to be inactivated in the liver in the 
absence of NFkB(115).  Efficient, long-term transduction and expression in the 
muscle can be attributed to rAAV9’s tropism(89). 
Expression of VLCAD in brown fat after systemic injection is novel. To our 
knowledge, there have been no reports that have shown transduction of brown 
adipose tissue and only two reports attempting to target white adipose tissue. 
Both reports used AAV1 and required an enhancing agent in order to get efficient 
transduction(120, 121).  In this report, we were primarily concerned with brown 
adipose tissue because of its important role in thermogenesis, which will be 
discussed in depth in Chapter 5. Brown fat differs from white adipose tissue in 
that it is highly vascularized, which gives rAAV9 easy access to brown adipose 
tissue when given systemically.  However that does not necessarily imply 
transduction or expression.  Transduction was also detected in other tissues 
including the brain, lung, lymph nodes, spleen and gonads.  De-targeting 
strategies such as capsid mutations and tissue specific promoters and 
microRNAs may be employed to minimize transduction and expression in 
unwanted tissues, if this ultimately proves to be necessary.  The expression 
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pattern of little to no transduction observed in female mice in the liver, however 
normal expression was detected in other tissues.    However it can easily be 
explained through androgen-dependent liver expression by AAV already 
documented in mice(119).  Although different serotypes experience more or less 
of this effect, rAAV9 sex-dependent expression has not been well 
characterized(122). Sex-dependent expression has not been detected in non-
human primates.  The expression pattern observed in female mice presents a 
potential tool for studying the liver’s role in correction of disease-specific 
phenotypes and will be discussed more in further chapters. 
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CHAPTER IV: Transduction of Brain after Systemic Injection 
Introduction 
Foust et al. were able to first show self complementary AAV9’s (scAAV9) 
(described in Chapter II) ability to cross the blood brain barrier (BBB) and 
transduce cells in the brain after systemic delivery(123).   After systemic injection 
with scAAV9, broad transduction was observed in neonates, whereas in adult 
mice expression was mostly in astrocytes of the brain.  They hypothesized that 
differences in transduction patterns were due to the underdeveloped BBB in 
neonates. However tight junctions which are responsible for some of the barrier 
function of the BBB, are fully developed during early development(124).  But it 
has been suggested that astrocytes’ endfeet are not fully developed, and are 
also present at low levels which may have an effect on transduction pattern 
differences reported between neonates and adults(124, 125).  Interestingly, when 
AAV9 is directly injected into the brain of adult mice it has little specificity for 
astrocytes.  Another possibility is that AAV is able to cross the BBB by receptor-
mediated transcytosis, as some AAVs have been shown to cross barrier 
endothelial and epithelial cells.  As the brain develops different receptors are 
expressed potentially accounting for differences in transduction patterns between 
neonates and adults(126). 
Other groups have shown single-stranded vectors are also able to cross 
the BBB; however, very limited results have been shown in adult mice(126, 127).  
All these studies used GFP as reporter gene for expression.  Currently only one 
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therapeutic study has been conducted by Fu et al., using single stranded rAAV9 
vectors in adult mice to treat mucopolysaccharidosis IIIB deficiency.  This study, 
although does not specifically assay for transduction since the therapeutic protein 
is secreted, did see significant reduction of disease specific phenotypes within 
different areas of the brain(128).  The mucopolysaccharidosis IIIB protein is 
unable to cross the BBB on its own, causing recombinant protein therapy to be 
unavailable for these patients.  But the rAAV could have transduced the brain 
vasculature, allowing for the protein to be secreted directly into the brain.  
Although some studies suggest that single stranded rAAV9 is unable to efficiently 
cross the BBB in adult mice(127) Fu’s work suggests that there may be enough 
expression for correction(128).   
In this study, we confirm expression of VLCAD protein after intravenous 
administration of single stranded rAAV9 in the brain of adult mice after our initial 
observation of surprising amounts of vector genomes in the brain. Here, VLCAD 
is used as reporter gene rather then a therapeutic gene as VLCAD protein is not 
highly expressed in the brain and does not play a known role in VLCAD 
deficiency in patients.  VLCAD expression is compared to the traditional reporter 
GFP, and found to be much easier to detect.  This study suggests that brain 
transduction after intravenous delivery of single stranded rAAV9 may currently be 
underestimated. 
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Materials and Methods 
Animals: 
VLCAD -/- mice were created by Exil et al. and purchased from Mutant 
Mouse Regional Resource Centers (MMRC, University of Missouri, MO). 
VLCAD-/- was created by breeding VLCAD-/+ animals creating VLCAD-/- and 
VLCAD+/+ littermate controls.   Balb/c and C57/B6 mice were purchased from 
Jackson Laboratories (Bar Harbor, ME). Mice were maintained in a pathogen-
free facility with 12hr light and dark schedule.  Mice were fed a standard chow 
and water ad libitum.   
All animal procedures were approved by University of Massachusetts 
Medical School Institutional Animal Care and Use Committee as well as 
University of Florida Institutional Animal Care and Use Committee in accordance 
with the Association for Assessment and Accreditation of Laboratory Animal Care 
International specifications.   
 
rAAV vectors: 
rAAV2/9 pseudotyped vectors were generated to express human VLCAD, 
of GFP under the transcriptional control of the cytomegalovirus enhancer/chicken 
β-actin promoter (CBA) (115).  rAAV vectors were produced, purified and tittered 
as previously described (UMMS Gene Therapy Center, Worcester MA)(117). 
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Genomic DNA extraction and Quantitative PCR: 
DNA was extracted and quantified as previously described(118). Animals 
were sacrificed at indicated time points and tissues were harvested in a manner 
to avoid cross-contamination, snap frozen in liquid nitrogen and stored at -80°C.  
Genomic DNA (gDNA) was extracted using a DNeasy blood and tissue kit 
(Qiagen Inc., Valencia, CA, USA) according to the manufacturer’s instructions. 
gDNA concentrations were determined using an Eppendorf Biophotometer 
(Eppendorf, Hamburg, Germany). 
 rAAV genome copies in the gDNA from brain, heart, liver, and tibialis 
anterior (TA) were quantified by qPCR with an ABI 7900 HT sequence detection 
system (Applied Biosystems, Carlsbad, CA, USA) according to the 
manufacturer’s instructions and results were analyzed using SDS 2.3 software.  
Briefly, primers and probe were designed to amplify SV40 poly-A tail of the 
rAAV9-CBA-VLCAD vector.  A standard curve was generated using plasmid DNA 
containing the same SV40 poly-A target sequence.  PCR reactions contained a 
total volume of 100µL and were run at the following conditions: 50°C for 2 
minutes, 95°C for 10 minutes, and 45 cycles of 95°C for 15 seconds and 60°C for 
one minute. 
DNA samples were assayed in triplicate.  In order to assay PCR inhibition, 
the third replicate was spiked with plasmid DNA at a ratio of 100-copies/µg 
gDNA.  If this replicate was greater than 40-copies/µg gDNA then the results 
were considered acceptable.  If a sample contained greater than or equal to 100-
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copies/µg gDNA it was considered positive for vector genomes.  If a sample 
contained less than 100 copies/µg gDNA it was considered negative for vector 
genomes.  If less than 1µg of gDNA was analyzed to avoid PCR inhibition, the 
vector copy number reported was normalized per µg gDNA and the plasmid 
spike in was reduced to maintain the ratio of 100-copies/µg gDNA. 
 
Immunohistochemistry: 
Tissues were fixed in 10% neutral buffered formalin, and embedded in 
paraffin.  Immunohistochemistry was carried out by the Molecular Pathology and 
Immunology Core at University of Florida.  Briefly, 4 µm serial sections were 
removed of paraffin and incubated with 3% H2O2 in methanol to block 
endogenous peroxidase activity. Sections were treated with Trilogy (Cell Marque, 
Rocklin, California) at 95° C for 25 minutes and blocked with Sniper (Biocare 
Medical, Walnut Creek, CA) to reduce non-specific background staining.  For 
GFP staining, several different antigen retrieval (AR) methods were tested 
including: no AR, Trilogy at 95°C for 25 minutes, Citrate at 95°C for 25 minutes, 
DAKO high at 95°C for 20 minutes and 20 minutes cool down on bench, DAKO 
low 95°C for 20 minutes and 20 minutes cool down on bench and Trypsin at 
37°C for 5 minutes.  Sections were incubated with rabbit anti-mouse VLCAD at 
room temperature for 1 hour. For GFP staining the following antibodies were 
tested: GFP raised in Rabbit (Cat#290, Abcam, Cambridge, MA); GFP raised in 
chicken (Cat#3839, Abcam, Cambridge, MA); AF488-conjugated GFP (Cat# A-
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21311, Invitrogen, Grand Island, NY).  Then sections were incubated with Mach2 
Gt x Rb HRP polymer (Biocare Medical, Walnut Creek, CA) for 30 minutes. 
Staining was visualized with DAB chromagen (Biocare Medical, Walnut Creek, 
CA). 
 
Confocal Microscopy: 
Slides were de-paraffinized with xylene and re-hydrated through 
decreasing concentrations of ethanol to water.  For heat-induced antigen 
retrieval, sections were heated in a water bath at 95°C while submerged in 
Trilogy buffer (Cell Marque, Hot Springs, AR) for 25 minutes.  Slides were 
subsequently rinsed in 1X tris-buffered saline (TBS) and sections were blocked 
for 20 min at room temperature with 10% normal goat serum. Next, sections 
were incubated with VLCAD (1:1000 dilution, homemade) overnight at 4°C 
followed by incubation with AF594 goat anti-rabbit IgG (Vector Laboratories, 
Inc.).  Avidin and Biotin kit (Vector Laboratories, Inc.) was used for 15 min to 
block endogenous avidin and biotin, separately. Then MOM kit (Vector 
Laboratories, Inc.) was used to block endogenous mouse IgG. A 1:400 dilution of 
B3-Tubulin antibody (Invitrogen, NY) was added to the samples for overnight 
incubation at 4°C. Then samples were washed twice with TBS, treated with the 
1:200 dilution of a biotinylated anti-mouse IgG and incubated at room 
temperature for 30 min. After washing with TBS, the sections were incubated 
with Fluorescein Avidin DCS (Vector Laboratories, Inc.) for 5 min. After being 
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washed twice with TBS for 5 min each, the slides were mounted with DAPI 
(Vector Laboratories, Inc.).  Slides were stored at 4°C until imaged using Perkin 
Elmer Ultraview spinning disc confocal microscope: Zeiss Axiovert 200M, 
×10 Plan-Apocromat NA 1.4 Oil objective, or ×63 Plan-Apocromat NA 1.4 Oil 
objective and Hamamatsu ORCA-ER camera. 
 
Results 
VLCAD-/- mice were tail vein injected with 200µl of single stranded rAAV9-
CB-VLCAD at 1x1012 vector genomes in per mouse and were sacrificed after 12 
weeks to look at long-term expression.  Brains were removed, sectioned and 
stained for VLCAD. Our initial observation of expression of VLCAD in cells with 
different morphologies (Figure 4.1) as well as throughout different sections of the 
brain is demonstrated by VLCAD staining in the Hippocampus (Figure 4.2) in 
cells with morphology similar to neurons and astrocytes, Cerebellum (Figure 4.3) 
in cells with morphology appearing to be purkinjie neurons and Choroid Plexus 
(Figure 4.4). 
In order to test if the expression detected was a result of a more 
permeable BBB in VLCAD-/- mice, different mouse strains: VLCAD+/+ 
background strain, C57/B6 and Balb/c mice were tested for transduction of 
VLCAD, 12 weeks post rAAV9 injection. Brains were sliced in coronal sections 
for both qPCR of vector genomes (Figure 4.6) and for histology (Figure 4-5).  
VLCAD+/+, C57/B6, and Balb/c mice all possess the VLCAD gene, however  
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Figure 4.1 AAV9 mediated VLCAD Expression in Cell types with Different 
Morphologies in the Brain 
Image of 10x magnification of VLCAD-/- mouse stained with VLCAD antibody 12 
weeks post-injection with rAAV9-VLCAD by systemic administration. Staining can 
be observed in cell types with different morphologies suggesting both astrocytes 
and neurons are being transduced. 
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Figure 4.2 AAV9 mediated VLCAD Expression in the Hippocampus 
Representative image at 10x magnification of the hippocampus of VLCAD-/- 
mouse brain stained with VLCAD antibody, 12 weeks post injection with rAAV9-
VLCAD by systemic administration.  Punctate staining is observed corresponding 
to mitochondrial expression. 
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Figure 4.3 AAV9 Mediated VLCAD Expression in the Cerebellum 
Representative image of the cerebellum at 10x magnification of a VLCAD-/- 
mouse stained with VLCAD antibody 12 weeks post-injection with rAAV9-
VLCAD. 
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Figure 4.4 AAV9 mediated VLCAD Expression in the Choroid Plexus 
Representative image of the Choroid Plexus at 20x magnification of a VLCAD-/- 
mouse stained with VLCAD antibody 12 weeks post injection with rAAV9-VLCAD 
by systemic administration.. 
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Figure 4.5 Expression of VLCAD in different Mouse Strains in the Brain 
Representative images of primary motor cortex at 10x magnification of Different 
mouse strains were injected with rAAV9-VLCAD. VLCAD staining was performed 
12 weeks post-injection.  Panel (a) depicts VLCAD -/- (b) depicts VLCAD+/+ (c) 
depicts Balb/c and (d) C57/B6. n=4 from each group.  
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Figure 4.6 AAV9 mediated VLCAD Transduction in the Brain of different 
Mouse Strains 
Different mouse strains were injected with AAV9-VLCAD and sacrificed 12 weeks 
post-injection. Brains were sliced into coronal blocks 2.0mm thick numbered 1-5, 
rostral-caudal.  Black bars depict VLCAD-/-, C57/B6 depicted by light gray bars 
and Balb/c depicted by dark gray bars.  Error bars denote SEM, and n=3 for each 
group. 
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VLCAD expression in the brain is very limited and only found at moderately low 
levels in the endothelial cells in the frontal cortex(33). Very low background 
staining was observed in VLCAD +/+ mouse strains. All four strains of mice had 
similar staining patterns and vector genomes of VLCAD throughout differing 
regions of the brain.  Overall there were no significant differences detected in 
either vector genomes, strain of mouse or different sections of the brain. 
To test if expression was time dependent, mice sacrificed at an earlier 
time point of 5 weeks post-injection were compared to animals sacrificed at 12 
weeks post injection.  Less staining overall in the cerebellum was observed at 5 
weeks post-injection in comparison to mice 12 weeks post-injection (Figure 4.7).   
Next to test if the increased expression in the brain was transgene 
specific, we injected VLCAD -/- mice with either vectors containing GFP or 
VLCAD.  Vector genomes to measure transduction were detected at 
approximately the same amount in mice injected with either GFP or VLCAD 
across all sections of the brain (Figure 4.8).  Interestingly, no GFP staining could 
be discerned across any of the brain sections, whereas VLCAD staining was 
readily observed in all sections and in many morphologically distinct cells (Figure 
4.1-4.9).  Six different antigen-retrieval protocols were tested as well as three 
different GFP antibodies, but no protocol or antibody produced reliable staining, 
however different fixations, such as frozen sections were not tested by may yield 
better results. When GFP and VLCAD transduction and expression were 
compared in other tissues, vector genomes were comparable in liver, TA muscle  
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Figure 4.7 AAV9 mediated VLCAD Expression at different time points post-
injection 
Representative VLCAD staining of Cerebellum sections at 5x magnification of 
VLCAD-/- mice after injection with AAV9-VLCAD.  Panel (a) depicts 5 weeks 
post-injection 5x, and panel (b) depicts 12 weeks post-injection.  n=4 for both 
time points. 
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Figure 4.8 Comparison of Transduction in mice injected with different 
transgenes 
Vector genomes were quantified from brains collected at 12 weeks post-injection 
from VLCAD-/- mice injected with either rAAV9-GFP or VLCAD.  Coronal 2.0mm 
sections of brains numbered 1-5, rostral-caudal.  Black bars represent VLCAD-/- 
mice injected with rAAV9-VLCAD and gray bars AAV9-GFP.  Error bars indicate 
SEM. n=3 for rAAV9-VLCAD and n=4 for rAAV9-GFP. 
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Figure 4.9 VLCAD and GFP expression in different tissues 
Tissues from VLCAD-/- mice were harvested at 12 weeks post-injection from 
either rAAV9-GFP or VLCAD injected animals.  Tissues were stained with either 
GFP or VLCAD antibodies respectively.  Representative images are shown from 
an n=4 for both groups. Magnification of liver, heart and muscle shown at 4x, 
Hippocampus at 20x.  a-d VLCAD expression in rAAV9-VLCAD injected animals 
 (a) Liver (b) Heart  (c) Muscle (d) Hippocampus, e-h GFP expression in rAAV9-
GFP injected animals (e) Liver (f) Heart (g) Muscle (h) Hippocampus  
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and brain (Figure 4.9-4.10).  Importantly in the liver, where average vector 
genomes were 1.3x107, GFP expression was readily detectable by 
immunohistochemistry (Figure 4.9,10).  However in the muscle, where average 
vector genomes of GFP were 1.8x105 lower than the 4.8x105 average vector 
genomes in the brain, no GFP staining was detected (Figure 4.10). 
Finally, to confirm that neurons in the brain were being transduced after 
single-stranded AAV9 injection into adult mice, confocal microscopy was 
performed. Sections from the hippocampus were fluorescently stained for using 
VLCAD and Tuj-1, neuronal specific class III beta-tubulin, antibodies.  Confocal 
microscopy confirmed the presence of transduced neurons (VLCAD+, Tuj-1+) 
within the hippocampus (Figure 4.11). 
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Figure 4.10 AAV9 Transduction comparison of VLCAD and GFP in different 
tissues 
Liver, TA muscle and brain were collected from mice 12 weeks post-injection with 
either rAAV9-VLCAD or rAAV9-GFP for vector genome quantification.  Black 
bars represent mice injected with rAAV9-VLCAD and Gray bars represent mice 
injected with rAAV9-GFP. Error bars represent SEM. n=7 for rAAV9-VLCAD, n=5 
for rAAV9-GFP. 
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Figure 4.11 Neuronal Expression of VLCAD by Confocal Microscopy 
Hippocampus section of VLCAD-/- mouse injected with 1x1012vg AAV9-VLCAD 
12 weeks post injection. Panel represents (a) 20x magnification and panel (b) 
63x magnification.  DAPI stain is blue. VLCAD stain is red, and Tuj-1, neuronal 
specific class III beta-tubulin, is green. 
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Figure 4.11 Neuronal Expression of VLCAD by Confocal Microscopy 
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Discussion 
Miyake et al., suggest that rAAV9 vectors are unable to cross the BBB if 
injected after 42 days post birth(127).  Here we show that rAAV9 vectors 
expressing VLCAD, injected systemically, are able to cross the BBB and 
transduce cells in the brain including neurons.  Our results may differ from the 
previous studies for multiple reasons: timeframe post-injection, mouse model 
used, vector dosage, and transgene expressed by rAAV9.  Miyake et al. detected 
no expression two weeks post-injection, and Gray et al. saw very limited 
transduction four weeks post-injection.  While this timeframe may be reasonable 
for self-complementary vectors, which can efficiently skip either the second 
strand synthesis or the self-annealing step, single stranded vectors may need 
more time before efficient expression can be observed.  Our data supports this 
argument as lower expression was observed five weeks post-injection compared 
to twelve weeks post-injection, as well as the work by Fu et al. where correction 
of the phenotype was assayed 6-9 months post-injection. 
Since the initial observation was made using VLCAD deficient mice, it was 
important to determine if the VLCAD deficient mice have an intrinsically more 
permeable BBB.  However, expression and transduction after systemic injection 
with rAAV9-VLCAD were similar in both C57/B6 mice, used in other studies, as 
well as Balb/c mice.  Our vector dosage of 1x1012vg, although higher than 
5x1011vg used by Gray et al., is a lower dose than the 1.5x1012vg dose used by 
Miyake et al.  Given that 1x1012vg is a relatively high dose, neither study, even at 
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the highest dose of 1.5x1012vg, was able to observe the extent of transduction 
and expression reported here. 
Finally, neuronal expression was confirmed by confocal microscopy.  
However expression of GFP, in spite of equivalent amounts of transduction 
distributed throughout the brain, was undetectable after several different 
strategies were attempted. However different processing and fixation of tissue 
may yield better results for GFP staining. Neither Gray et al., nor Miyake et al., 
quantified vector genomes, and only Gray at el. observed very low levels of GFP 
staining after enhancing the signal by an avidin-biotinylated enzyme complex, 
which was not used in these experiments. 
The discrepancies between GFP and VLCAD expression could simply be 
explained by the antibody sensitivity, but alternative possibilities exist.  Unlike 
GFP, which resides in the cytosol, VLCAD is expressed at the inner 
mitochondrial membrane producing a well-defined punctate pattern of staining 
throughout the brain.  This expression pattern may concentrate signal, over the 
diffuse expression of GFP. Clearance of GFP may be even higher than VLCAD. 
Even though VLCAD is being used as a reporter gene as it is not expressed in 
the brain for therapeutic benefit(33), it is still a self gene, has a role, and is 
compartmentalized in the mitochondria even if not expressed in VLCAD-/- mice.  
Expression of GFP can be toxic and Gray et al., showed that GFP expression 
caused transient liver toxicity after systemic injection(126).  Also, the half-life of 
GFP is approximately 26 hours, which could also cause the staining to be less 
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apparent.  In these studies mRNA levels for either GFP or VLCAD were not 
studied, nor were in situ hybridizations used.  Therefore low levels of expression 
of GFP protein in the brain could also account for the differences observed, even 
though vector genomes are approximately the same between GFP and VLCAD.  
Taken together, regardless of mechanistic explanations of why GFP 
expression is undetectable at low transduction efficiencies, these studies suggest 
GFP reporter assays in the brain may underestimate expression of other 
transgenes.  In the only study using a single stranded vector encoding a 
therapeutic gene rather than a reporter gene, Fu et al. was able to see 
remarkable correction of the mucopolysaccharidosis IIIB phenotype even at a low 
dose.  The results presented here allow for more potential therapeutic options by 
using single stranded vectors, that have more packing space then self-
complementary, and adult administration for diseases that will not be diagnosed 
or treated until adulthood.  It is currently unknown whether rAAV9 or any of the 
other serotypes will be able to cross the BBB in humans after systemic injection, 
but work with self-complementary vectors crossing the BBB in adult nonhuman 
primate and large animal models is promising(126, 129).   If rAAV is able to cross 
the BBB in humans, there are numerous therapeutic applications for these 
vectors. 
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CHAPTER V: Gene Therapy for VLCAD- Biochemical and 
Phenotypic Correction 
Introduction 
VLCAD deficiency is the most common disorder of long chain fatty acid 
metabolism, with a regional incidence in the United States of 1 in 30,000 births, 
and second in frequency only to MCAD deficiency among disorders of fatty acid 
oxidation. (130, 131)  Characterized by the most severe phenotype within the 
acyl-CoA dehydrogenase deficiency family, patients generally present with one of 
three distinct clinical phenotypes.  Of these three phenotypes the earliest onset 
presentation during infancy is the most severe, presenting with cardiomyopathy 
and hepatopathy and are often fatal(132).  A less severe hepatic phenotype 
presenting with recurrent hypoketotic hypoglycemia, also occurs in infancy to 
early childhood.  The third phenotype is a mild, myopathic form presenting in 
adolescence or adulthood with muscle weakness, myalgia and 
myoglobinuria(133, 134).  
VLCAD is responsible for catabolism of long chain fatty acids, with highest 
specificity for carbon lengths C14-C18, as part of the mitochondrial beta-
oxidation spiral.  It is the rate-limiting enzyme in the process, causing an energy 
deficiency as well as accumulations of long chain fatty acids.  Beta-oxidation is 
an important source of energy for liver and muscle, especially cardiac muscle. 
The disease is associated with a lack of energy caused by the inability to 
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breakdown long chain fatty acids but the accumulates of these long chain fatty 
acids can also be detrimental(135, 136). The amassments of these metabolites 
are exploited for diagnostic purposes as part of the newborn screening by 
analyzing for acyl carnitine metabolite accumulations in the blood by tandem 
mass spectrometry (MS/MS).  Although newborn screening has reduced 
mortality, the current treatment is limited to fasting avoidance, and 
supplementation of medium chain triglycerides (MCT), which remains 
controversial since supplementation of MCT in excess of the immediate caloric 
demand will induce the production of longer chain fatty acids for storage as 
triglycerides(18). These in turn will add to the total load of longer chain fatty 
acids, which cannot be subsequently metabolized when caloric restriction occurs.  
Therefore, VLCAD deficiency is a candidate for gene therapy because of its 
limited treatment options as well as its potentially fatal phenotype. 
The Flotte laboratory has previously shown biochemical correction of 
SCAD deficiency by targeting muscle with rAAV1 and rAAV2, and liver with 
rAAV8 as well as LCAD deficiency by targeting the muscle with rAAV1(106, 107, 
110).  New AAV serotypes, such as AAV9, have improved expression and wider 
transduction profiles(89, 116). Merritt and colleagues showed limited biochemical 
correction of VLCAD deficiency using systemic injections with AAV8. Here we 
present the first evidence of a genetic therapy that systemically targets major 
tissues involved in beta-oxidation, has long term expression and corrects several 
disease-specific phenotypes in a VLCAD deficient mouse model. 
70
 
Materials and Methods 
Mass Spectrometry: 
Blood acyl carnitines were extracted, derivatized and analyzed as 
described previously(137).  The following labeled carnitine standards (Cambridge 
Isotope Laboratories, Andover MA) were used for quantification: L-carnitine (N-
trimethyl-D9), L-Acetylcarnitine (N-methyl-D3), L-propionylcarnitine (N-methyl-D3), 
L-Butyrylcarnitine (N-methyl-D3), L-Isovalerylcarnitine (N-trimethyl-D9), L-
Octanoylcarnitine (N-methyl-D3), L-Myristoylcarnitine (N-trimethyl-D9) and L-
Palmitoylcarnitine (N-methyl-D3).  Blood acyl carnitine samples were analyzed as 
butyl esters on a Micromass Quattro II (Manchester UK) with an electrospray 
ionization source operating in the positive ion mode by direct infusion.  Tissue 
samples were processed as previously described(138).  In brief, frozen tissue 
samples were ground into powder and resuspended in 80% acetonitrile 
containing carnitine standards described above at a concentration of 60mg/ml.  
Samples were homogenized and centrifuged, supernatants were dried under 
nitrogen.  Samples were then resuspended in 10% acetyl chloride in 1-butanol 
and heated at 65°C for 15 minutes, dried under nitrogen and brought up in 80% 
acetonitrile for analysis.  Samples were run in triplicate on a Waters (Milford, MA) 
Premier XE triple quadrupole mass spectrometer similarly to the blood samples. 
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1H-MRS: 
Single voxel 1H-MRS was obtained from the TA muscle and liver at 11.1T 
and 4.7T respectively.  11.1T localized proton muscle spectra were obtained 
using a Bruker spectrometer (PV3) as described previously(106).  A custom-
made loop gap coil with 1.4-cm inner diameter tuned to 470.5 MHz was used. 
Localizer anatomical proton magnetic resonance images were acquired using 
FLASH (matrix, 256 x 256; echo time (TE)=4.3 msec; repetition time(TR)=207 
msec, FOV=20X20mm2) were acquired in three orthogonal directions for the 
precise localization of a volume of interest (VOI) from which proton MRS would 
be obtained. Water suppression was optimized by chemical shift-selective 
(CHESS) water suppression. Localized spectra were acquired by point-resolved 
spatially localized spectroscopy (PRESS) (TE=18 msec; TR=3,000 msec; 
number of excitations (NEX)=512, bandwidth=8013Hz, number of complex 
points=2,048). Data were processed using 
jMRUI(http://www.mrui.uab.es/mrui/mrui Overview.shtml). Similarly localized 
single voxel proton liver spectra were obtained at 4.7T using PRESS (TE=14 
msec; TR=2,500 msec; NEX=16, bandwidth=3,005Hz, number of complex 
points=8,196) on a Varian/Agilent spectrometer (VnmrJ).  Liver MRS was 
processed using in house software (IDL; ITT) in order to determine the integral of 
water and lipid resonances.  
Animals were fasted for 18-24 hours before bleeds, magnetic resonance 
spectrometry or cold fast challenge.  For cold fast challenge, after the 18 hour 
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fast, mice were singly housed in minimal bedding cages and placed in a 4°C cold 
room for 150 minutes or until rectal temperatures were below 20°C.  Blood 
glucose levels were measured by Nova Max Glucose Monitor and Strips (Nova 
Biomedical Corporation, Waltham MA). 
All animal procedures were approved by University of Massachusetts 
Medical School Institutional Animal Care and Use Committee as well as 
University of Florida Institutional Animal Care and Use Committee in accordance 
with the Association for Assessment and Accreditation of Laboratory Animal Care 
International specifications. 
Results 
Because VLCAD deficient patients have a greater magnitude of 
accumulation of long chain acyl carnitines in the blood, it was essential to 
demonstrate biochemical correction of whole blood by measuring acyl carnitine 
accumulates by electrospray tandem mass spectrometry (MS/MS).  Prior to 
treatment, and on days 14, 42 and 140 post-injection, male mice were subjected 
to a 24-hour fast followed by whole blood collection.  Metabolic stress such as 
fasting was required to observe optimal response. Large accumulations of long 
chain metabolites were found in VLCAD-/- PBS controls and reductions of the 
levels of C14, C16:1, C16, C18:2, C18:1 and C18 were revealed 14 days post-
injection in rAAV9-treated VLCAD-/- animals when compared to VLCAD-/- PBS 
controls (Fig. 5.1).  There were no significant differences between controls, 
AAV9-GFP or PBS, so PBS was used as a control for subsequent experiments  
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Figure 5.1 Reduction of Acyl Carnitines in the blood of rAAV9-VLCAD 
treated mice 
All animals were fasted 24 hours prior to bleeding.  Designates p< 0.05, 
**p<0.01, ***p<0.001, ****p<0.0001. Quantities of acyl carnitine species were  
assessed by mass spectrometry of whole blood day 14-post injection.  n=7 
untreated VLCAD-/- controls, n=6 rAAV9 treated VLCAD-/- mice; and n=6 in 
wildtype controls. Error bars are SEM.    P-values are as follows: C14 p=0.002, 
C16:1 p=<0.0001 C16 p=0.0008 C18:2 p=0.005, C18:1 p=0.005, C18 p=0.04 
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(Figs. 5.2a-c). It was noted that reductions in blood acyl carnitines were observed 
across all groups between the first and second 24-hour fasting time points, 
regardless of treatment, age, or if mice remained uninjected (Fig. 5.3,4,5,6), a 
phenomena that is also observed in our MCAD mice. Significant reductions in 
levels of C16, C18:1, C18 (Figs. 5.4,5,6), P<0.0006, in whole blood persisted for 
over 140 days post-injection of rAAV9-VLCAD when compared to the PBS 
controls.  These reductions, which were observed out to 140 days post injection, 
infer biochemical correction of the whole blood. 
Biochemical correction within the liver tissue itself was assessed by an in 
vivo and ex vivo approach.  Using single voxel proton magnetic resonance 
spectroscopy (1H-MRS), lipid accumulations in the liver were measured in live 
animals 17 weeks post- injection.  Figure 5-7A shows representative liver spectra 
from VLCAD-/- PBS control, VLCAD-/- AAV9 treated and VLCAD+/+ PBS control 
mice.  A measure of total lipid, the ratio of the area under the lipid peak divided 
by the area under the water peak, as an internal control is shown in Figure 5.7B.    
No significant differences were detected in accumulations measured by MRS 
between the VLCAD-/- and VLCAD+/+ or rAAV9-treated groups.  Ex vivo acyl 
carnitine accumulations were measured by MS/MS of the liver tissue in Figure 
5.8.  Significant differences in C16, C18:2, C18:1 and C18 were  
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Figure 5.2 Levels of Acyl Carnitines in rAAV9-VLCAD with GFP Control   
All mice were fasted 24 hours before blood collection. n=3 for VLCAD-/- PBS, 
n=3 for VLCAD-/- AAV9-GFP control, n=4 VLCAD-/- AAV9 VLCAD treated, n=4 
for VLCAD+/+  (a) Mass Spectrometric quantification of C16 in whole blood. 2-
way ANOVA Between PBS Control and AAV9-GFP p=0.67(b) Mass 
Spectrometric quantification of C18 in whole blood.  2-way ANOVA Between PBS 
Control and AAV9-GFP p=0.94 (c) Mass Spectrometric quantification of C18:1 in 
whole blood.  2-way ANOVA Between PBS Control and AAV9-GFP p=0.64  
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Figure 5.2 Levels of Acyl Carnitines in rAAV9-VLCAD with GFP Control   
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Figure 5.3 Acyl Carnitine Profiles in blood of uninjected mice over time 
All mice were uninjected, and fasted for 24-hours prior to blood collection.  
Panels a,b and c had an n of 4 for VLCAD+/+ and an n of 5 for VLCAD-/-.  
Panels d, e and f had an n of 2 for 6-8 week old VLCAD+/+, n of 2 for 16-18 
weeks old VLCAD +/+, n of 2 for 6-8 weeks old VLCAD-/- and n of 3 for 16-18 
week old VLCAD-/-.  Age is designated by age at first fasting-bleed.  (a) Mass 
Spectrometric analysis of accumulations of C16 in whole blood over 12 weeks. 
(b) Mass Spectrometric analysis of accumulations of C18:1 in whole blood over 
12 weeks. (c) Mass Spectrometric analysis of accumulations of C18 over 12 
weeks.  (d) Mass Spectrometric analysis of accumulations of C16 in whole blood 
over 12 weeks. (e) Mass Spectrometric analysis of accumulations of C18:1 in 
whole blood over 12 weeks. (f) Mass Spectrometric analysis of accumulations of 
C18 over 12 weeks. 
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Figure 5.3 Acyl Carnitine Profiles in blood of uninjected mice over time 
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Figure 5.4 MS/MS quantification of C16 in the whole blood over time 
All animals were fasted 24 hours prior to bleeding. ***Designates p<0.001. 
Untreated VLCAD-/- controls Day 0 and 14 n=11; Day 6 n=3; D140 n=7.  rAAV9 
Treated VLCAD-/- mice Day 0 and 14 n=11; Day 6 n=5; D140 n=6. Wildtype 
control mice Day 0,14 n=11; Day 6 n=5; D140 n=6. Error bars are SEM.  A 2-way 
ANOVA was preformed on data from Day 14-Day 140 with p= 0.0006. 
 
  
80
 
Figure 5.5 MS/MS quantification of C18:1 in the whole blood over time 
All animals were fasted 24 hours prior to bleeding.  ***Designates p<0.001.  
Mass Spectrometric quantification of C18:1 over time. Untreated VLCAD-/- 
controls Day 0 and 14 n=11; Day 6 n=3; D140 n=7.  rAAV9 Treated VLCAD-/- 
mice Day 0 and 14 n=11; Day 6 n=5; D140 n=6. Wildtype control mice Day 0,14 
n=11; Day 6 n=5; D140 n=6.Error bars are SEM.  A 2-way ANOVA was 
preformed on data from Day 14-Day 140 with p= 0.0003 
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Figure 5.6 MS/MS quantification of C18 in the whole blood over time 
All animals were fasted 24 hours prior to bleeding.  Designates ***p<0.001.  
Mass Spectrometric quantification of C18 over time. Untreated VLCAD-/- controls 
Day 0 and 14 n=11; Day 6 n=3; D140 n=7.  rAAV9 Treated VLCAD-/- mice Day 0 
and 14 n=11; Day 6 n=5; D140 n=6. Wildtype control mice Day 0,14 n=11; Day 6 
n=5; D140 n=6.Error bars are SEM.  A 2-way ANOVA was preformed on data 
from Day 14-Day 140 with p= 0.0014. 
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Figure 5.7 Biochemical analysis of lipids in the liver in vivo  
 (a) Representative spectra from magnetic resonance spectrometry of liver in 
vivo. 17–18 weeks post-injection. (b) Quantification of the ratio of the area of the 
lipid peak/area of the water peak. Error bars are SEM. n = 3. 
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Figure 5.8 Biochemical analysis of Acyl Carnitines in the liver ex vivo  
Mass spectrometric analysis of liver tissue ex vivo, 21–25 weeks post-injection; 
 n = 7 untreated VLCAD−/− controls, n = 6 rAAV9-treated VLCAD−/− and wild-type 
controls. Error bars are SEM. Samples were analyzed in triplicate. No significant 
difference between any of the groups. 
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observed between the VLCAD-/- PBS control and VLCAD+/+ mice (Figure 5.8).  
Unexpectedly, reductions were not distinguished in the liver of the VLCAD-/- 
rAAV9-treated animals, despite the significant reductions observed in whole 
blood. 
Analogously, we assessed biochemical correction in the muscle tissue 
employing the same in vivo/ex vivo approach.  Figure 5-9a is an MRI image of a 
representative muscle where the 1H-MRS spectrum was taken.  Representative 
spectra from VLCAD-/- PBS control, VLCAD-/- rAAV9-treated and VLCAD+/+ 
PBS control mice are shown in Figure 5.9b.  The ratio of the area under the lipid 
peak was divided by the area under the taurine, tri-methyl ammonium and 
creatine total peak, as the internal control for muscle.  Comparison of VLCAD-/- 
PBS control, VLCAD-/- rAAV9-treated and VLCAD+/+ PBS control mice, lipid 
peak ratios are shown in Figure 5.9c.  The VLCAD-/- PBS control mice had 
accumulation of lipids within the muscle whereas the VLCAD-/- rAAV9 treated 
exhibited reduced lipid content similar to wildtype mice. Acyl carnitine 
accumulations were observed from ex vivo tissue by MS/MS for both the 
extensor digitorum longus (EDL), primarily composed of fast twitch muscle, and 
the soleus (SOL), primarily composed of slow twitch fibers.  Reductions of long 
chain accumulations were observed in both the EDL (Figure 5.10a) and SOL 
(Figure 5.10b) in the rAAV9 treated animals.   Furthermore, expression of 
VLCAD in the skeletal muscle reduced accumulations of acyl carnitines within the 
tissue. 
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Figure 5.9 Biochemical analysis of lipids in the muscle in vivo  
(a) Magnetic resonance image (MRI) of hindlimb muscle 12–14 weeks post-
injection. (b) Representative spectra from MRS of muscle in vivo. (C) 
Quantification of the ratio of the area of the lipid peak/area of the taurine–creatine 
peak. n = 7 untreated VLCAD−/− controls, n = 6 rAAV9-treated VLCAD−/− animals 
and wild-type controls. No statistical difference between any groups.   Error bars 
are SEM. 
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Figure 5.9 Biochemical analysis of lipids in the muscle in vivo  
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Figure 5.10 Biochemical analysis of Acyl Carnitines in the muscle ex vivo  
 (a) Mass spectrometry of extensor digitorum longus (EDL) ex vivo 21–25 weeks 
post-injection. n = 7 untreated VLCAD−/− controls, n = 6 AAV9-treated VLCAD−/− 
and wild-type controls. Error bars are SEM. Differences were as follows: C16 P = 
0.09, C18:2 P = 0.06 C18:1 P = 0.06 C18 P = 0.05. Samples were run in 
triplicate. (b) Mass spectrometry of soleus (SOL) ex vivo 21–25 weeks post-
injection. n = 7 untreated VLCAD−/− controls, 6 rAAV9 VLCAD−/− and wild-type 
controls. Error bars are SEM. Statistics were as follows: C16 NS, C18:2 P = 
0.001, C18:1 P = NS, C18p = NS. 
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Figure 5.10 Biochemical analysis of Acyl Carnitines in the muscle ex vivo  
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Cardiomyopathy can be a presenting symptom in patients with VLCAD 
deficiency(139, 140).   Since expression was widespread in the heart (Figure 
2.2), a question remained if biochemical correction of the cardiac tissue had 
occurred. Cardiac tissue was analyzed by MS/MS of acyl carnitines extracted 
from ex vivo tissue.  Acyl carnitines in cardiac muscle were at or below wildtype 
levels in rAAV9-treated mice whereas VLCAD-/- PBS controls had large 
accumulations (Figure 5.11).  Expression of VLCAD in cardiac muscle, facilitated 
by rAAV9, was able to correct VLCAD-/- animals to wild-type levels of acyl 
carnitines in the cardiac tissue instead of large accumulations observed in 
VLCAD -/- animals. 
Cold can induce metabolic derangement in VLCAD deficiency patients, as 
production of heat requires fatty acid oxidation especially after dietary fat stores 
have been used up (141). VLCAD deficient mice are also unable to maintain 
body temperatures during a cold challenge, and it has been shown to be fatal 
especially when combined with fasting (142). To assay for disease specific 
phenotypic correction, a cold fast challenge was utilized, in which the mice are 
fasted for 18 hours followed by a cold challenge in a 4°C room for 2.5 hours.  
During the challenge, a humane sacrifice was performed for animals with a body 
temperature below 20°C as determined by IACUC.  In Figure 5.12a, the  
VLCAD-/- AAV9-treated and wildtype animals were able to maintain average 
body temperatures of 26.15°C and 26.4°C respectively for 150 minutes.  
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Figure 5.11 Reduction of Acyl Carnitines in the heart 
Mass spectrometry of heart tissue ex vivo at 21–25 weeks post-injection. n = 7 
untreated VLCAD−/− controls, n = 6 AAV9 VCLAD−/− and wild-type controls. Error 
bars are SEM. Statistics were as follows: C16 P = 0.003 C18:2 P = 0.005 C18:1 
P = 0.004 C18 P = 0.005.  
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Figure 5.12 Temperature maintenance and survival of rAAV9- VLCAD 
treated mice after cold fast challenge 
 (a) Core body temperature of mice undergoing cold fast challenge, temperatures 
were recorded every 20 minutes by rectal thermometer. Mice were humanely 
sacrificed if body temperatures dropped below 20 °C, n = 4. Error bars are SEM. 
P ≤ 0.0001 by two-way analysis of variance (ANOVA) of temperature and time 
(starting at 20 minutes in cold until 150 minutes) between VLCAD-/- PBS Control 
and VLCAD-/- AAV0-VLCAD Treated. (b) Survival of cold fast challenge. 
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Figure 5.12 Temperature maintenance and survival of rAAV9-VLCAD 
treated mice after cold fast challenge 
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However, PBS control VLCAD-/- animals were unable to maintain body 
temperatures above 20°C, with two animals being euthanized at 110 minutes the 
remaining two animals at 130 minutes. To summarize, by 150 minutes into the 
cold challenge all of the PBS control VLCAD-/- animals had internal temperatures 
that dropped below the humane sacrifice point, whereas all the VLCAD -/- AAV9 
treated, and wildtype animals survived (Fig. 5.12B).  Lethargy and hypotonia are 
often a presenting symptom when VLCAD deficient patients are undergoing a 
period of metabolic crisis(136). PBS control VLCAD deficient animals became 
lethargic and hypotonic during the cold fast challenge (Video 5.1). In contrast, 
rAAV9-treated animals as well as the wildtype animals did not display lethargy 
and hypotonia as can be appreciated (Video 5.2 and 5.3).   
Hypoketotic hypoglycemia is a primary presenting symptom in VLCAD 
deficient patients.   Blood glucose levels were compared in all three strains, in 
fed, fasted and cold challenge state.  There were no significant differences 
between any of the groups at the fed levels, however blood glucose levels were 
significantly reduced following both fasting and cold challenge in the PBS control 
VLCAD deficient animals when compared to the wild type mice (Fig. 5.13). In 
contrast, the rAAV9-VLCAD treated animals fully corrected glucose levels to that 
of wildtype under both fasted and cold conditions.  One wildtype mouse out of 
four had a blood glucose level of 278mg/dl, which drove the average up in the 
wildtype after the cold fast challenge. However, blood glucose levels after the  
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Figure 5.13 Maintenance of blood glucose in rAAV9-VLCAD treated mice 
after cold fasting challenge  
Blood glucose levels during fed, fasted and fasted plus cold challenge conditions, 
n = 4. Error bars are SEM. No significant difference at fed state between all 
groups or between rAAV9-treated animals and wild-type under any condition, 
Significant differences were observed between rAAV9-treated VLCAD-/- animals 
and PBS treated VLCAD -/- after cold fast challenge P = 0.005. 
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cold fast challenge, were not significantly different from the VLCAD-/- rAAV9-
treated and the wildtype mice, whereas VLCAD-/- animals blood glucose levels 
were significantly reduced.   
Interestingly rAAV9-VLCAD treated female mice, which received the same 
vector and dose but had little to no VLCAD expression in the liver, did not show 
reduction of accumulates of long chain acyl carnitine after fast like the male 
counterparts(Figure 5.14). Although an initial drop is reported two weeks post 
injection in VLCAD-/- VLCAD treated mice, which is commonly observed across 
all groups and even in uninjected mice (Figure 5.3), the accumulation levels 
return to what is observed VLCAD-/- PBS controls.   Opposite of the levels 
detected in male mice, which were corrected and were more similar to VLCAD 
+/+ mice after VLCAD injection.  The female mice did however have similar 
levels of expression of VLCAD in other tissues (Figure 3.4).   
When the rAAV9-VLCAD treated female mice underwent the cold fasting 
challenge on one hand, they were able to better maintain body temperatures 
then VLCAD-/- PBS treated females, like their male counterparts (Figure 5.15).  
On the other hand they were unable to maintain temperatures as well as 
wildtype, unlike the male counterparts.  rAAV9-VLCAD treated female mice were 
able to maintain temperatures at wildtype levels for 90 minutes, at which point 
one VLCAD-/- PBS treated mouse’s temperature dropped below the critical  
temperature.  However, by the end of the study at 150 minutes, two out of three  
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Figure 5.14 MS/MS quantification of C16 in the whole blood over time in 
female mice 
All animals were fasted 24 hours prior to bleeding. Mass Spectrometric 
quantification of C18:1 over time.  n=10 for week 0 & 2 and n=4 for weeks 4 & 8 
for all groups. 
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Figure 5.15 Temperature and survival of female rAAV9-VLCAD treated mice 
after cold fast challenge 
 (a) Core body temperature of mice undergoing cold fast challenge, temperatures 
were recorded every 20 minutes by rectal thermometer. Mice were humanely 
sacrificed if body temperatures dropped below 20 °C, n = 4. Error bars are SEM. 
(b) Survival of cold fast challenge 
 
  
98
 
 
Figure 5.15 Temperature and survival of female rAAV9-VLCAD treated mice 
after cold fast challenge 
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rAAV9-VLCAD treated females temperatures dropped below the humane point 
and had also become lethargic.  It should be noted that female VLCAD-/- mice in 
general were more susceptible to the cold fast challenge, as their temperatures 
dropped below 20°C from 90-110 minutes whereas the male mice did not drop 
below 20°C before 130 minutes.  The difference may be accounted for by males 
have significantly larger body weight and insulating fat stores.  rAAV9-VLCAD 
treated female mice also became hypoglycemic after fasting and the cold fast 
challenge, similarly to VLCAD-/- PBS controls (Figure 5.16).  Unlike the male 
rAAV9-VLCAD treated mice they were not able to maintain glucose levels 
through a fast or cold fast challenge, and behaved more similarly to untreated 
VLCAD -/- mice. 
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Figure 5.16 Blood glucose in female rAAV9-VLCAD treated mice after cold 
fast challenge 
Blood glucose levels during fed, fasted and fasted plus cold challenge conditions, 
n = 3. Error bars are SEM.  
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Discussion 
Phenotypic correction of multiple disease-specific phenotypes, including 
blood acyl carnitines, thermoregulation, resistance to lethargy, and blood glucose 
maintenance was demonstrated here using rAAV9-mediated gene therapy in a 
male mouse model of VLCAD deficiency.  A clinically translatable non-invasive 
technique, MRS, was employed to measure correction within the muscle and 
liver. In vivo MRS results confirmed the MS/MS findings ex vivo in the tissues.  
Within the liver tissue, lipid accumulates were mildly reduced as detected by 
MRS and MS/MS but not to the extent distinguished in other tissues such as 
skeletal muscle.  No previous work concerning correction of disorders of fatty 
acid oxidation have employed MS/MS of tissue samples to measure 
accumulations of acyl carnitines within tissues themselves. Correction of SCAD 
using rAAV8 demonstrated reduction of liver accumulates by MRS but used a 
liver targeted approach injecting into the portal vein(107). Expression within the 
liver was observed after systemic injection used in this study.  The VLCAD 
staining pattern in the liver is different from that within the cardiac and skeletal 
muscle where it is widespread but at a low level of expression. Within the liver, it 
appeared that certain cells expressed VLCAD at very high levels, while other 
cells did not express at all.  However without efficient targeting of the liver, 
reduction of accumulates in the blood as well as maintenance of blood glucose 
levels would not be expected, as noted in the female mice.  This variable VLCAD 
expression pattern may cause the correction discrepancy between whole liver 
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extract accumulations and the impact of the liver on reducing whole blood 
accumulates and maintaining blood glucose levels.  It was noted that expression 
within the liver directly correlated with reduction of acyl-carnitine accumulates 
within in the tissue itself.  Individual mice with the most expression displayed the 
most reduction, whereas individual mice with the least expression had large 
accumulations within the liver.  Also as androgen-dependent transduction of the 
liver was shown to be important in female mice, differential expression of 
testosterone may account for variable levels of expression across mice, however 
these levels were not tested.  This phenomenon of variable expression in the 
liver has been previously reported using rAAV8(143).  
Brown fat plays an important role in non-shivering thermogenesis by 
expressing UCP-1 protein, which allows uncoupling of oxidative phosphorylation 
and the production of heat.  Brown fat has a vital role in thermogenesis in human 
newborns, and is present and functional in adult humans although to a lesser 
extent(144).  The pronounced ability of rAAV9-treated VLCAD-/- mice to 
thermoregulate body temperature in a cold environment compared to the 
untreated mice clearly demonstrates correction of the cold sensitive phenotype.  
The role brown fat plays in the phenotypic correction of these mice has yet to be 
determined; however it is suspected that brown fat is not solely responsible for 
temperature maintenance during the cold fast challenge as the female mice were 
unable to maintain body temperatures at wildtype levels in spite of brown fat 
transduction.  However, they were not as susceptible to cold temperatures as the 
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VLCAD-/- mice were, suggesting that brown fat, cardiac or skeletal muscle or 
even multiple systems also play important roles in thermogenesis. Work by 
Skilling and colleagues(145) suggests that brown fat does not play as strong a 
role in VLCAD deficient sensitivity to cold as it does in shorter chain deficient 
animals such as SCAD.  They suggest that rapid consumption of glycogen in the 
liver and muscle as well as impaired ability to shiver and decreased cardiac 
function is responsible for cold sensitivity(145). Unlike other disorders of fatty 
acid oxidation no energy can be produced by fatty acid oxidation in VLCAD 
deficient individuals, as VLCAD is the rate-limiting enzyme. Exil and 
colleagues(146) reported that VLCAD deficient animals succumb to bradycardia 
during the cold fast challenge. Therefore both shivering, heat produced through 
muscle contraction, and non-shivering, heat produced through uncoupling of 
oxidative phosphorylation in the brown fat, thermogenesis may play a role in the 
defect in thermoregulation in these mice. rAAV mediated expression of VLCAD in 
liver, allowing the animal to produce ketones which can go on to produce energy 
in other tissues, may have a larger impact on thermogenesis than expression of 
VLCAD in the brown fat as VLCAD deficient mice retain 80% residual activity in 
the brown fat(145).  Also rAAV-mediated expression of VLCAD in the muscle 
may allow for heat production through shivering.  Interestingly, carnitine 
palmityoltransferase 1a (CPT1a) heterozygous mice, the liver isoform of CPT 
enzyme, are not cold intolerant but heterozygous (CPT1b), the muscle/heart 
isoform (CPT1b) are cold intolerant suggesting the importance of long chain fatty 
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acid oxidation in the muscle and heart for thermogenesis(4).  Correction of 
multiple tissues, as demonstrated in the male mice, may be necessary in order to 
see correction of this phenotype. 
 Current standard of care for VLCAD patients is primarily dietary, limiting 
long chain fatty acids and supplementing with medium chains as well as 
avoidance of fasting.  Studies have shown effectiveness, especially when 
administered prior to exercise(20, 21). However, even with screening and 
treatment, approximately 10-20% of patients suffer episodic 
rhabdomyolysis(147). Supplementation of medium chain triglycerides has come 
under question since patients can suffer myopathic symptoms despite treatment 
and studies in VLCAD-deficient mice have shown muscle phenotypes after 
exercise on fat-reduced carbohydrate-enriched diets(148).  Also mice fed a diet 
of medium chain triglycerides had accumulations of visceral fat, liver lipids and 
tissue fat composition changed significantly(18). Although patients diagnosed by 
newborn screening have greatly reduced mortality associated with all disorders 
of fatty acid oxidation, sudden death has still been reported(46).  Having a 
therapy rather than treatment options could vastly improve patients’ quality of life.  
This work provides proof-of-concept for rAAV9-mediated gene therapy for 
VLCAD deficiency. 
 
 
 
105
CHAPTER VI: Discussion 
Taken together the work presented here has significant implications for 
both clinical and basic sciences.   We have presented not only a potential 
therapy for VLCAD deficiency, but also more generally developed useful tools for 
the basic understanding of the roles specific tissues play in mitochondrial fatty 
acid oxidation.  Also in the course of this work, a novel method for transduction of 
brown fat by single-stranded rAAV9 was discovered, as well as efficient 
expression across the brain in cells of different morphologies, after systemic 
injection in adult mice.   The therapeutic benefits of efficient brain transduction 
after non-invasive administration have a number of potential clinical applications.  
Clinical applications of brown fat expression have yet to be explored.  However, 
rAAV9-VLCAD expression may also have a therapeutic benefit of increasing 
levels of fatty acid oxidation for different disorders where fatty acid oxidation 
rates are low.  One group recently showed that in mice, rAAV1 delivery to the 
liver of carnitine palmitoyltransferase 1A (CPT1A) and a permanently activated 
form of CPT1A protected against weight gain, steatosis, diabetes and obesity-
induced insulin resistance after induction of a high fat diet; and moreover in a 
genetically obese mouse model, reported reduced glucose and insulin levels and 
liver steatosis(149).   
VLCAD deficiency is a recessive single gene disorder that affects multiple 
organs and is detectable by newborn screening but yet has no known definitive 
treatment.   Moreover it has a heterogeneous phenotype with some patients 
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presenting with a cardiomyopic phenotype, others with a liver phenotype and still 
others with a muscle phenotype.  The presenting symptoms are not exclusive 
between phenotypes and can often change with time. With the advent of better 
therapeutic vectors, the possibility of targeting multiple tissues with one vector is 
now available.  Multiple tissue targets were desirable here as an important proof-
of-concept that biochemical correction could be achieved in all three organ tissue 
targets.   
Moving forward a more targeted gene therapy approach may be possible.  
Vector selection is generally based on the target tissue for expression of the 
therapeutic protein.  In the case of secreted proteins, the tissue targeted for 
transduction and expression of the therapeutic protein is not always the tissue 
where the protein will have the therapeutic benefit.  The muscle is an ideal 
clinical candidate for ectopic expression as it is easily accessible, has a large 
mass, and potentially less detrimental if a severe side effect occurred.  For 
example, a recent clinical trial by Flotte et al. uses the muscle to express the 
secreted alpha-1 anti-trypsin protein where the therapeutic effect is in the lungs 
of the patients(103).  
 In the work described here, VLCAD is associated with the inner 
mitochondria membrane, and therefore not secreted, however VLCAD’s 
substrate, long-chain fatty acids, are able to freely enter into and out of cells, but 
must be transported into and out of the mitochondria. In a disorder like SCAD or 
disorders of peroxisomal degradation, where disease phenotypes are generally 
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associated with toxic accumulates and not with energy deficiencies, it could be 
suggested that one organ could act as a metabolic sink for a systemic 
therapeutic effect.  SCAD also benefits from short and medium chains not 
requiring active translocation across the mitochondria membrane.  Conlon et al. 
and Beattie et al., were both able to show systemic reduction of blood acyl-
carnitine accumulations after targeting the muscle and liver respectively, in 
SCAD deficiency(106, 107).  However the disease phenotype for long chain fatty 
acid disorders is not only associated with toxic accumulations but more 
importantly an energy deficiency. When Beattie et al. tried to target muscle in 
LCAD deficient mice using rAAV1, correction of blood acyl-carnitine 
accumulations were not detected, although reduced hepatic microsteatosis was 
reported in female mice(110).  In studies presented here, female mice suggest 
that muscle correction alone, although expression of VLCAD was measured in 
many other tissues besides skeletal muscle, was not sufficient for reduction of 
acyl-carnitine accumulations, maintenance of temperature or blood glucose 
under fasting and cold conditions.  Even if the muscle correction would show 
biochemical correction of accumulates, it is unlikely that it could treat the energy 
deficiency suffered in other organs such as heart or liver, as once long-chain fatty 
acids have started beta-oxidation they are unlikely to leave the treated muscle 
cell and travel to an untreated liver or heart cell.  All VLCAD deficient patients 
have the ability to break down long chain fatty acids in their peroxisomes, which 
is capable of oxidizing fatty acids until they reach a chain size of eight carbons, 
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but yet a phenotype for this disease still exists in deficient patients.  Severity of 
disease and wide heterogeneous phenotype in these patients may be related to 
the amount of compensation peroxisomal oxidation can provide. Alternatively, 
muscle expression may not have been high enough in female mice to produce 
systemic correction in the female mice and a more targeted muscle approach 
may be able to show systemic correction. 
Interestingly, there is an organ that can produce energy that can 
subsequently be transferred systemically.  The liver’s ability to produce ketones, 
which can be broken down to produce energy in other tissues, allows for hope of 
a tissue-specific correction of VLCAD by potentially treating both the energy 
deficiency and toxic accumulations.  Long chain fatty acids could be metabolized 
in the corrected cells of the liver, thus removing toxic accumulations, and also 
producing ketones. From the liver those ketones released into the blood which 
can go to the heart, whose preferred energy source is fatty acid oxidation, or the 
brain which prefers glucose for energy production but uses ketones under 
glucose limiting conditions.  Tissue specific expression restricted to the liver was 
not studied in this work, but could have important therapeutic relevance in the 
future. 
 
Defense of Gene Therapy for VLCAD Deficiency 
  A large number of genetic therapy targets are often diseases with 
devastating outcomes and where patients have little hope.  Although VLCAD 
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deficiency is not associated with drastically reduced lifespan and quality of life it 
is highly associated with sudden death.  With the advent of newborn screening 
for these disorders infant sudden death has been drastically decreased, but has 
been by no means eliminated.  VLCAD can still be fatal during early infancy in 
spite of newborn screening(147).  There have been 20 reported cases of sudden 
death in MCAD deficienct patients, which is less severe then VLCAD deficiency, 
even when MCAD deficient status was known and 3 of the patients were 19 
years or older at death(46).  Also mild adult onset phenotypes can sometimes 
become more severe. One VLCAD case report describes a 32 year old patient, 
who previously had recurrent muscular weakness and a family history of a 
brother who died of Reye’s syndrome at 17 years of age, presented with coma, 
persistent hypoglycemia, rhabdomyolysis and acute cardiomyopathy requiring 20 
days in intensive care unit, but was successfully discharged after 13 weeks(150).  
Any period of metabolic decomposition in a patient with a FAO disorder, although 
acute, can be fatal and severely detrimental.   
 Current treatments for VLCAD deficiency other than low-fat dietary 
restrictions and avoidance of fasting, are not well studied and inefficient. Many 
severe patients must be fed through gastrostomy tubes especially at young ages. 
Also as patients are usually exercise restricted and told to eat regularly on a 
frequent schedule, patients often have excessive weight gain in spite of low-fat 
diets.  Non-compliance is also often an issue with these disorders since under 
normal conditions these patients can appear perfectly healthy.  However any 
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seemingly mild illness can cause rapid metabolic decomposition.  Extra care 
must also be taken in any perioperative period, as patients can have severe 
complications(15). 
On current standard MCT treatment, 10-20% of patients still experience 
rhabdomyolysis.  The three patients described in the triheptanoin study, who 
were currently on MCT therapy given by gastrostomy were described as: 5 years 
old patient unable to stand from sitting, climb stairs or open heavy doors without 
assistance, hepatomegaly and symptoms of mild cardiomyopathy, 9 year old who 
had very limited exercise capacity due to pain, attention deficient disorder and 
mild hepatomegaly, and a 2 year old who was unable to support his own weight 
when lifted through his arms and could not run for more then 10-15 feet without 
stumbling(26).  The last two patients would be considered in the mild muscle 
phenotype because no hypoglycemia or cardiomyopathy was reported.  
Moreover the standard treatment of MCT supplementation has not been well 
studied in the long-term and mouse studies have produced concerning results.  
Studies have shown that supplementation prior to exercise has benefits but long-
term supplementation leads to hepatic steatosis, oxidative stress, disrupted fat 
distribution and composition (18, 20, 148, 151) 
 Even among the experimental therapies outlined in Chapter I, very limited 
therapies have been suggested that could treat all VLCAD phenotypes. 
Bezafibrate and resveratrol only help patients with mild disease and some 
enzyme activity.  Other treatments are mostly palliative and are not well studied.  
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Gene therapy for VLCAD, as well as other long-chain FAO defects and acyl-CoA 
deficiencies, would allow for curative therapies for all phenotypes associated with 
disease as well as phenotypes that might develop with age.  Retinopathies 
associated with mTFP and LCHAD may be able to be corrected through gene 
therapy approaches as rAAV eye gene therapies have had clinical success(152). 
Through these proof-of-concept studies, non-invasive evaluative tools such 
Magnetic Resonance Spectrometry were performed which would allow for 
potential tracking of clinical outcomes in patients.   
Perhaps most importantly, this work demonstrated that correction of 
biochemical and defects correlated with disease-specific phenotypes under 
conditions of physiologic stress, such as the cold fasting challenge.  The type of 
phenotypic correction is crucial for demonstrating the feasibility of therapeutic 
benefits for VLCAD gene therapy in a clinical setting.  Based on these findings, 
gene therapy for these disorders may have a clear clinical benefit for affected 
patients.  Future steps toward clinical gene therapy are already in progress, as a 
collaboration is being formed with a leading clinical group in this field at Oregon 
Health Sciences University.  Formal pharmacology and toxicology studies will be 
needed to satisfy FDA requirements, but these should provide a straightforward 
path to the clinic for this disorder. 
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CHAPTER 7: Additional Projects: Aberrant Immune Responses 
in CFTR-/- mice 
Introduction 
Cystic fibrosis (CF) is the most common autosomal recessive genetic 
disease in the US, affecting 1 in 3,300 live births; and the result of mutations in 
CFTR, a chloride channel and regulator of other ion channels. CF patients suffer 
a wide range of clinical consequences from the disease, including pancreatic 
insufficiency, with subsequent malabsorption and impaired nutrition, and chronic 
airway infection with Pseudomonas aeruginosa and other pathogens(153).  The 
mechanisms by which CFTR mutations cause chronic lung disease in CF are not 
fully defined, but may include the combined effects of altered ion and water 
transport across the airway epithelium(154-156), increased binding or decreased 
clearance of Pseudomonas aeruginosa (157, 158) as well as increased pro-
inflammatory cytokine production in the CF airway (159-163). CF cell lines 
demonstrate increased NFkB activation and increased IL-8 secretion in response 
to P. aeruginosa exposure, as compared with control cells (163, 164). 
Furthermore, CFTR mutant mice demonstrate a greater cytokine response (KC, 
MIP2, IL-1beta), greater mortality, and weight loss after airway challenge with a 
P. aeruginosa-agarose bead slurry, as compared with control mice (165-168).   
 
Allergic broncho-pulmonary aspergillosis (ABPA) is a clinical syndrome 
characterized by recurrent wheezing and pulmonary infiltrates, an excessively 
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high total serum IgE, and high IgE and IgG antibodies directed against 
Aspergillus fumigatus (Af), which is usually found to be colonizing the airways of 
these patients.  ABPA is common in CF, affecting approximately 15% of all 
patients (169, 170).  It is occasionally recognized in patients with asthma, 
although some studies have shown that up to 50% of asthma patients with ABPA 
have at least one mutation in the CFTR gene (171-174). The immune response 
in ABPA appears to be an IL-4-driven, Th2-predominant response that is 
observed in CF patients and in the Cftr mutant mouse expression profiling 
studies (175-178).  Based on this observation, our laboratory has recently 
described an ABPA-like model in CF mice (179). In subsequent studies we 
observed divergent cytokine production in splenocytes from the Cftr mutant mice 
challenged with Af antigen (180). This led us to question whether the differences 
in inflammatory signaling in CF mice are due to the direct or indirect effects of 
Cftr mutations within lymphocytes.   
This question has been raised in previous work (181, 182).  Studies 
conducted immediately following the discovery of CFTR indicated that 
lymphocyte chloride transport was defective in CF and could affect function 
under certain circumstances (183).  A number of other studies have shown that 
CFTR gene replacement could restore lymphocyte channel activity to normal 
(184, 185). Finally, the Th2-bias of CF lymphocytes have been confirmed by a 
number of investigators (176, 177). In this report, we investigated whether there 
are primary defects in lymphocytes lacking CFTR function. Furthermore, we 
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propose a possible mechanism for this increased response in lymphocytes, in 
which aberrant calcium fluxes lead to an increase in the nuclear localization of 
NFAT, a transcriptional regulator of cytokines driving the Th2-biased response. 
 
Materials and Methods 
Mouse strains: 
The Cftr knock-out strain used for these studies was the CFTR S489X -/- 
neo insertion in C57BL/6 mice developed initially at the University of North 
Carolina (186) and then modified with the transgenic over  expression of gut-
specific expression of human CFTR from the fatty acid binding protein (FABP)- 
promoter in order to prevent intestinal obstruction and improve viability (187).  
The other mouse strain used is Cftr-ΔF508 mouse, both mouse strains have 
been backcrossed 10 generations onto a C57BL/6 mouse. For experiments on 
conditional knockout mice the recently developed floxed Cftr mouse (188) was 
crossed with the C57BL/6 mice expressing CRE recombinase under the control 
of the leukocyte-specific protein tyrosine kinase (LCK) promoter.  
Aspergillus sensitization and challenge: 
Animals were sensitized to Aspergillus fumigatus crude protein extract (Af-
cpe) (Greer Laboratories). Briefly, animals were administered with intraperitoneal 
(i.p.) injections of 200ug of Af-cpe extract dissolved in 100ul of PBS on days 0 
and 14. Aerosol challenge was performed with 0.25 % Af-cpe for 20 min in a 
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30x30x20 cm acrylic chamber using a jet nebulizer Pari model LC-D with an air 
flow of 6 liters/min on days 28, 29 and 30.   
 
Adoptive Transfers: 
Adoptive transfers were performed by harvesting either Af-cpe sensitized 
or naïve splenocytes from Cftr-ΔF508 (Cftr-/-) or wildtype littermate controls. 
Briefly, spleens were disaggregated in Hank’s buffer saline and passed through a 
20um mesh. Cells were then resuspended in PBS at a concentration of 4.5x108 
cell/ml. Rag-/- mice on a C57BL/6 background were then injected intra-
peritoneally with 100ul of the suspension. Eight weeks were allowed for 
engraftment before either challenging or sensitizing and challenging Rag-/- mice.  
 
Antigen Recall:  
Spleens were harvested and CD4 T cells and CD11b cells were separated 
using the AutoMACs pro (Miltenyi Biotec).  Cells were counted and plated in 96 
well round bottom plates so that there were 1 x 105 CD4 T cells and 1 x 105 
CD11b positive cells for a total of 2 x 105 cells per well.  Cells were cultured in 
media that contained 10mg/ml albumin (Sigma).  After 3 days supernatants were 
removed and frozen for cytokine analysis using Luminex Technology (Bio-Rad, 
Hercules CA). 
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Intracellular Calcium Flux: 
Spleens were harvested and CD4 T cells were separated using 
AutoMACS pro (Miltenyi Biotec).  Intracellular Calcium staining was carried out 
as previously described (189).   
 
NFAT Studies: 
Splenocytes from Cftr-ΔF508 (Cftr-/-) or wildtype littermate controls were 
plated on paired round bottom 96 well plates with RPMI 1640 10% FBS and 1% 
Pen/Strep at a concentration of 1x105 cells/well.  The cells were then stimulated 
with CD3/CD28 antibody cocktail and wells from one plate were harvested at (10, 
30 and 90 min.). For nuclear protein extraction while the other was used to obtain 
cell culture supernatants at (1.5, 3, 6 and 24 hrs) for cytokine analysis. Nuclear 
NFAT translocation was assayed from the nuclear extracts using the modified kit 
TransAM NFATc1 (Active Motif). Cell culture supernatants were analyzed for 
cytokine secretion profiles using Luminex Technology (Bio-Rad, Hercules CA). 
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Results 
In previous studies, we have shown that Cftr-/- mice on a mixed 
background had IgE levels that were 2-5 fold higher than their controls when 
sensitized and airway challenged with Aspergillus fumigatus crude protein extract 
(Af-cpe)(179). Furthermore, this phenotype was partially corrected after Cftr gene 
replacement with recombinant adeno-associated vectors(180). Here we further 
establish the phenotype by comparing total serum IgE levels in Cftr-/- mice that 
are on a congenic C57BL6 background. Cftr-/- and Cftr+/+ littermates were 
sensitized and challenged with Af-cpe as previously described. Total serum IgE 
from congenic mice littermates challenged with Af-cpe were on average two-fold 
higher for Cftr-/- mice (Figure 7.1).  
To determine if Cftr-/- lung epithelial cells were responsible for higher IgE 
response towards Af-cpe, we designed adoptive transfer experiments 
transferring Cftr-/- immune cells into Rag-/- mice hosts that where otherwise 
normal for Cftr. In the first set of experiments, Cftr-/- mice with a deletion of 
phenylalanine at amino acid position 508 of the Cftr gene (ΔF508, the most 
common mutation in the CF population) were sensitized but not airway 
challenged with Af-cpe. We then harvested splenocytes from these mice and 
their wildtype littermate controls and adoptively transferred them via an intra-
peritoneal injection into Rag-/- mice of the same C57BL6 genetic background. 
Eight weeks post transfer the Rag-/- mice were airway challenged with 
aerosolized Af-cpe. Since Rag-/- are deficient in T and B cells and can not  
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Figure 7.1 Total serum IgE levels in congenic C57B6 CFTR−/− mice and 
their littermates after Af sensitization and challenge  
Mice were sensitized with 200 µg of Af crude extract dissolved in 100 µl of PBS 
on Days 1 and 14. Blood samples were collected on Day 32, 48 hours after the 
third aerosol Af challenge. Total serum IgE in the Af-sensitized mice was 
measured by ELISA. Data are shown as group averages (±SEM). 
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produce IgM, total circulating IgM levels were measured to verify engraftment 
(Figure 7.2B). In order to determine if sensitized splenocytes from CF mice alone 
were able to recapitulate the high IgE phenotype in a wildtype (Cftr+/+) airway, 
sera from the adoptively transferred Rag-/- mice was checked for IgE levels. The 
two-fold enhanced IgE phenotype is transferred into the host by the adoptive 
transfer of sensitized splenocytes (Figure 7.2A). To rule out the possibility of 
other Cftr-deficient tissues having an effect on the sensitization of the immune 
cells that were transferred, we repeated these experiments by transferring naïve 
splenocytes into naive Rag-/- mice. Eight weeks after the naïve splenocyte 
transfer, Rag-/- mice were sensitized and airway challenged with Af-cpe.  Again 
the experiments recapitulated the hyper-IgE phenotype as serum levels of Rag-/- 
mice receiving CF splenocytes were also two-fold higher than Rag-/- mice 
receiving wildtype splenocytes (Figure 7.2C). In contrast, IgM levels in these two 
groups were not different, confirming that the difference in IgE antibodies levels 
was not due to differences in B-cell engraftment (Figure 7.2D).  
We then designed a series of antigen recall experiments in order to 
determine what cell population of the splenocytes was responsible for polarizing 
the adaptive Th2 immune responses. In these experiments, splenocytes from 
mice that had been sensitized to ovalbumin (OVA) were magnetically sorted into 
either CD4+ lymphocytes or CD11b+ monocytes. The rationale for using OVA 
stimulation was that in vitro the monocytes would process the antigen and 
present it to the OVA specific T cells, allowing one to monitor the cytokine  
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Figure 7.2 Adoptive transfer of CF splenocytes confers elevated IgE 
phenotype 
CFTR-ΔF508 (CFTR−/−) mice on the C57BL/6 background or matched control 
C57BL/6 mice (CFTR+/+) were used as donors for splenocyte adoptive transfer 
into B6-Rag−/− mice. Total serum IgE (A and C) and IgM (B and D) were 
measured after Af challenge. (A and B) CFTR-ΔF508 (n = 6) and C57BL/6 
littermates (n = 6) were sensitized with Af–crude protein extract (Af-cpe), and 2 
weeks after sensitization their splenocytes were transferred into Rag−/− mice, 
where they were allowed to engraft for 8 weeks before airway challenging the 
mice. (C and D) Naive CFTR-ΔF508 (n = 10) and naive C57BL/6 littermates (n = 
10) were used to harvest naive splenocytes for transfer into Rag−/− mice. 
Splenocytes were allowed to engraft for 8 weeks, and then Rag−/− mice were 
sensitized and airway challenged with Af-cpe. 
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Figure 7.2 Adoptive transfer of CF splenocytes confers elevated IgE 
phenotype 
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profiles secreted in response to a specific antigen. To determine if the Th2 
polarization was due to either antigen presentation or to the antigen-specific 
response by T-cells the cell populations were paired in the following 
configuration; CF monocytes with CF T-cells, CF monocytes with wildtype T-
cells, wildtype monocytes with CF T-cells or wildtype monocytes with wildtype T-
cells.  These experiments uncovered three main cytokine secretion patterns. First 
elevated secretion of Th2 cytokines IL-4 and IL-13 was dependent on whether 
the stimulated cells had CF CD4+ T cells and was independent of the monocyte 
source (Figure 7.3A-B). A different cytokine secretion pattern was observed for 
IL-17 and IL-5; this one was synergistic and dependent on whether both the 
antigen presenting cell population (Cd11b+) and the effector cell population 
(CD4+) were Cftr-/- (Figure 7.3C-D). Finally IL-2 secretion was similar among all 
combinations demonstrating that the altered cytokine secretion patterns are not 
an experimental artifact resulting from the cell mixtures (Figure 7.3E).  
To confirm the hypothesis that deficiency in functional CFTR in T cells 
results in Th2 biased adaptive immune response and leads to higher IgE levels, 
we used conditional Cftr knockout mice. These studies were carried out by 
crossing the recently described Cftr floxed mice (188) with mice expressing Cre 
recombinase under the control of the leukocyte-specific protein tyrosine kinase 
(Lck) promoter, which drives expression of Cre recombinase  in CD3+ 
lymphocytes, resulting in the knockout of the Cftr gene in both CD4+ and CD8+ 
T-cells.  
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Figure 7.3 In vitro antigen recall with mixed cell populations  
Splenocytes from congenic CFTR−/− or CFTR+/+ mice sensitized to ovalbumin 
(OVA) were separated into both CD11b+ and CD4+ cell populations with 
magnetic beads. Cells were mixed and “crossed” to make four groups of cell 
preparations: (1) CF CD11b+ with CF CD4+ cells; (2) CF CD11b+ with wild-type 
(WT) CD4+ cells; (3) WT CD11b+ with CF CD4+ cells; and (4) WT CD11b+ with 
WT CD4+ cells. Cells were then stimulated with OVA for 5 days. The cell culture 
supernatants were analyzed for cytokine profiles at Day 5. Data are shown as 
group averages (±SEM). 
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Figure 7.3 In vitro antigen recall with mixed cell populations  
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The floxed Cftr gene was maintained as a homozygous allele and mice 
were crossed to yield both mice that were Lck-Cre+, and thus Cftr deficient in the 
T-cell population and mice that were Cre- and thus maintaining the functional 
floxed Cftr gene in all tissues and cell types. Interestingly, IgE levels in naïve Lck-
Cftr-/- mice showed a significant upregulation of serum IgE even at basal levels 
when compared to their littermate controls (Figure 7.4). This suggests an 
inherently Th2-biased commitment of Cftr deficient T-cells even in the absence of 
stimulation. Next we sensitized and airway challenged these mice along with 
their littermate controls with Af-cpe. The results further confirmed a role for Cftr 
expression in T cells as evidenced by the divergence in serum IgE levels 
developing at day 21 (1 week after the 2nd i.p injection) and through day 32 (48 
hrs after the final aerosol challenge) (Figure 7-5). 
To elucidate possible mechanisms for the CFTR channel altering 
lymphocyte activation, we tested a recently described model suggesting a link 
between CFTR and intracellular calcium (iCa2+). While, iCa2+ concentration can 
be controlled by multiple mechanisms including: calcium channels, plasma 
membrane Ca2+ ATPase pumps, and potassium channels among others, the 
model suggests that the Cftr mutation can cause altered iCa2+ and its eventual 
signaling and inflammation. Suggesting that CFTR’s effect on cell membrane 
potentials alters the electrical driving force for Ca2+ to enter the cells. In Cftr+/+ 
T84 intestinal epithelial cells it has been demonstrated that changes in 
membrane potentials caused expected changes in iCa2+ during agonist activation  
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Figure 7.4 Total serum IgE levels in naive conditional CFTR-/- mice 
T cell conditional knockout mice created by crossing the floxed Cftr mouse with 
mice expressing the Cre recombinase expressed from the leukocyte-specific 
protein tyrosine kinase (Lck) promoter were compared with control animals that 
were Cftr floxed, but Cre recombinase negative. Basal serum IgE levels were 
analyzed by ELISA. Data are shown as group averages (±SEM). 
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Figure 7.5 Total serum IgE levels in Af-cpe–sensitized conditional CFTR-/-
mice 
T-cell Cftr knockout mice (Cftr floxed and Lck Cre+) along with WT controls (Cftr 
floxed and Cre−) were sensitized with 200 µg of Af crude extract dissolved in 100 
µl of PBS on Days 1 and 14. Blood samples were collected on Days 21, 28, and 
32. Total serum IgE in the Af-sensitized mice was measured by ELISA. Data are 
shown as group averages (±SEM). 
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of calcium entry pathways (190, 191). Thus, with a reduction in Cl- permeability 
in Cftr-/- cells their membranes can hyperpolarize and it is predicted that Ca2+ 
entry across the cell membrane would be increased. Alterations in this pathway 
are important because in lymphocytes, iCa2+ initiates a signal transduction 
pathway through calmodulin and calceneurin eventually leading to the activation 
of  nuclear factor of activated T-cells (NFAT).  NFAT has been shown to enhance 
gene expression of IL-4, IL-13, IL-5, TNF-alpha cytokines among others (192).   
 To test the above hypothesis and whether the CFTR deficient T cells 
would have an effect on iCa2+ signaling through the T cell receptor (TCR), we 
measured intracellular calcium fluxes in CD4+ T-cells in response to CD3/CD28 
stimulation of the TCR. Measurements of intracellular calcium in CD4+ T cells 
using the calcium sensitive Indo-1 dye revealed a significantly greater and 
enhanced calcium flux response in Cftr deficient T cells (Figure 7.6).   
To show that the increased intracellular calcium fluxes detected in TCR activation 
in response to CD3/CD28 results in nuclear accumulation of NFAT, we 
performed a time course where T cells from splenocyte preparations were 
stimulated with same CD3/CD28 antibody cocktail. Nuclear extracts from the 
stimulated cells were prepared and used to measure NFAT levels. The results 
confirm that NFAT is translocated to the nucleus in a time sensitive manner after 
TCR activation, by CD3/CD28, and that this nuclear localization is significantly 
increased in Cftr deficient T cells (Figure 7.7).   
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Figure 7.6 Intracellular calcium (iCa2+) flux  
Changes in the concentration of intracellular free Ca2+ ions are measured by 
monitoring the change in its emission spectrum of Indo-1 dye from blue to violet 
upon binding to Ca2+. The blue emission is measured through a 530/30 band 
pass filter, and the violet through a 405/20 band pass and 405 low pass filter; 
thus, a shift in the violet: blue ratio over time is a reflection of the increase in 
iCa2+ concentration. CD4+ cells were enriched (see inset, top left) from Cftr-
ΔF508 and Cftr+/+ mice and stimulated with anti–CD3/CD28 antibodies (Abs), 
followed by 500 ng/ml of ionomycin (as a positive control; see inset on bottom 
right). (A) Representative iCa2+ flux for Cftr-ΔF508 and Cftr+/+ CD4+ T cells. (B) 
The area under the curve for the traces from Cftr-ΔF508 (n = 6) and Cftr+/+ (n = 
6) in response to CD3/CD28 Abs. (C) Slopes for the traces from Cftr-ΔF508 (n = 
6) and Cftr+/+ (n = 6) in response to CD3/CD28 Abs. 
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Figure 7.6 Intracellular calcium (iCa2+) flux  
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Figure 7.7 NFAT nuclear translocation and cytokine secretion in Cftr−/− and 
Cftr+/+ mice after T cell receptor stimulation. 
 (A) Nuclear translocation of NFATc1 was measured using a modified ELISA 
from nuclear splenocyte extracts after CD3/CD28 stimulation at 10, 30, and 90 
minutes after stimulation. Parallel plated cells were assessed for cytokine 
expression after CD3/CD28 stimulation at 1.5, 3, 6, and 24 hours. (B) Time 
course expression for TNF-α. (C) Expression of IL-13 at 24 hours after 
stimulation. Data are shown as group averages (±SEM) for a total of n = 5. 
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Figure 7.7 NFAT nuclear translocation and cytokine secretion in Cftr−/− and 
Cftr+/+ mice after T cell receptor stimulation. 
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To directly show if this nuclear translocation of NFAT would also translate 
to an upregulation and increased secretion of IL-13 in Cftr-/- T-cells, we 
measured the cytokine levels in the supernatants of CD3/CD28 stimulated cells. 
The data showed that the secretion pattern of TNF-alpha, an early activated 
cytokine known to respond to iCa2+ signaling through the T cell receptor (193) 
mimicked the pattern of NFAT and was secreted at significantly higher levels 
from Cftr-/- T cells (Figure 7.7B). While IL-13 was below detection in the earlier 
time points it was found to be expressed at significantly higher levels from Cftr-/- 
T-cells in supernatants collected 24hrs after stimulation (Figure 7.7C).   
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Discussion 
In the present study, we demonstrate for the first time that CFTR deficient 
lymphocytes leads to an inherent divergence in the adaptive immune response in 
vivo. Specifically, in this case it is characterized by an aberrant Th2-biased 
immune response to Aspergillus fumigatus that is dependent on CFTR function in 
lymphocytes alone. We demonstrated that sensitization and aerosol challenge of 
Cftr-/- mice and their wildtype controls leads to an enhanced-IgE response in 
Cftr-/- mice that is reminiscent of CF related allergic asthmatic condition known 
as allergic broncho-pulmonary aspergillosis (ABPA).  While ABPA remains rare 
outside of the CF population it is common among CF patients, affecting 
approximately 15% of them(169, 170). Interestingly, we demonstrated that the 
transfer of naive Cftr-deficient splenocytes into congenic Rag-/- mice was enough 
to confer the high IgE response to the Rag-/- mice. These experiments revealed 
that a CFTR dependent phenotype could be transferred from CF mice into CFTR 
sufficient hosts purely through splenocytes.  
The expression of CFTR in lymphocytes has been well characterized 
throughout the years, (182, 185, 194) however the physiological relevance of 
CFTR expression in lymphocytes is less clear, with some studies implicating it 
with volume regulation and cytolysis regulation of CD8+ T-cells(195-198). Other 
models suggest that activation of Cl- currents by CFTR in response to nitric oxide 
via a cyclic GMP-dependent mechanism are defective in T cells from CF 
patients(199). Importantly, electrophysiological studies document a functional 
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role for CFTR in lymphocytes by recording a defect in cAMP-dependent Cl- 
currents in CF- derived lymphocytes using whole cell patch clamp 
techniques(182, 200). These studies demonstrate the presence and function of 
CFTR within lymphocytes and lend some credence to the longstanding yet 
controversial view that a primary immune abnormality is associated with cystic 
fibrosis. To date it has been difficult to separate aberrant immune response 
observed in CF from the disease phenotype imparted by epithelial cell 
dysfunction. Our adoptive cell transfer experiments indicate that a primary 
immune abnormality is indeed a possibility. Namely, the transfer of naïve 
splenocytes was able to recapitulate the 2-fold higher IgE response observed in 
Cftr-/- mice. We further investigated what specific cell type from the splenocyte 
pool was responsible for this phenotype with in vitro assays. Since the IgE 
response is known to be driven by Th2 cytokines and we have previously 
demonstrated that IL-13 is upregulated in Cftr-/- mice challenged with Af-cpe, we 
designed a series of experiments to analyze the secretion of Th2 cytokines by 
activated T cells in response to antigen.  According to our data, a marked 
difference in the secretion of IL-4, IL-13, IL-5 and IL-17 was observed from CD4+ 
and CD11b+ cells that were Cftr deficient. Interestingly, antigen specific 
responses characterized by increased secretion of IL-4 and IL-13 were only 
observed in the presence of Cftr-/- CD4+ T cells, whereas the increased 
secretion of IL-5 and IL-17 seemed to be dependent on a synergistic interaction 
between both Cftr-/- Cd11b+ and CD4+ cells. Taken together with the adoptive 
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transfer experiments these data suggested that Cftr deficient T-cells imparted a 
Th2-skewed response, characterized by increased secretion of IL-4 and IL-13 
ultimately leading to the high IgE response directed against Aspergillus fumigatus 
crude protein extract. However, based on the secretion of IL-5 and IL-17 in the 
antigen recall experiments, it is conceivable that skewed responses may be due 
to the interaction of various Cftr deficient immune cells, such as macrophages, 
dendritic cells and T-cells. 
In order to directly determine whether this phenotype can be attributed to 
Cftr deficient T-cells we created T-cell specific Cftr knockout mice by using a 
floxed Cftr mouse expressing Cre recombinase under the control of the LCK 
promoter. These mice presented with an increase in basal IgE levels in the 
absence of any exogenous antigenic stimulus. These elevated basal IgE 
circulating antibody levels are consistent with a previous observation in which we 
recorded higher IgE levels in Cftr-/- mice, as compared to controls which had 
been mocked-PBS sensitized and challenged with Af-cpe(179). Furthermore, 
these T-cell Cftr conditional knockout mice went on to develop dramatically 
different IgE responses to Af-cpe as was characteristic of Cftr-/- mice. With these 
experiments we were able to finally demonstrate without any confounding 
variables a primary immune abnormality associated with cystic fibrosis in vivo, 
which, to our knowledge has never been shown before.  
A consequence of Cftr deficiency in lymphocytes is the reduction in Cl- 
permeability, which in turn may hyperpolarize their membranes. It is 
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hypothesized that the altered membrane potential could then alter the electrical 
driving force for Ca2+ to enter the cells. Here we also show that intracellular 
calcium fluxes in Cftr-/- CD4+ T cells are increased in response to CD3/CD28 
stimulation as determined by the area under the curve and the slopes of the Ca2+ 
flux response when compared to wildtype CD4+ T cells (Figure 7.6). The 
relevance of this altered calcium flux in Cftr-/- T-cells is that it may lead to 
increased transcription activity of Ca2+ regulated transcription factors. Nuclear 
factor of activated T-cells (NFAT) activity is modulated by cytoplasmic Ca2+ 
concentration through various Ca2+ associated signaling pathways. Ultimately, 
any increase in cytoplasmic Ca2+ concentration induce NFAT dephosphorylation 
and NFAT translocation to the nucleus where it binds to cis regulatory elements 
of target genes as a monomer(201). This signaling cascade proceeds through 
calmodulin and calcineurin, a cytoplasmic serine/threonine phosphatase. 
Calcineurin upregulates NFAT by dephosphorylating serines in the SP-repeats 
and in the serine rich N terminus region of NFAT exposing the nuclear 
localization signal, allowing NFAT to translocate to the nucleus(201). In T cells, 
TCR stimulation causes an increase in intracellular Ca2+ concentration depleting 
Ca2+ sequestered ions in the ER, followed by an influx of extra-cellular calcium 
ions from Ca2+ release activated Ca2+ channels (CRAC)(201). While NFAT 
activation regulates a variety of immune processes, NFAT has been found to 
regulate a number of other promoters for cytokine genes, including those 
involved in the regulation of Th2 immune responses as IL-4, IL-13, IL-5 and TNF-
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alpha(202). In agreement with the results for the intracellular Ca2+ flux 
experiments we observed a significantly greater increase in the nuclear 
translocation of NFAT after TCR activation with CD3/CD28 in Cftr-/- cells (Figure 
7.7). Parallel cell experiments demonstrated that following NFAT nuclear 
translocation Cftr-/- cells had significantly higher expression of TNF-alpha and 
the key Th2 effector cytokine IL-13. These data suggests that a possible 
mechanism responsible for the in vivo immune aberration observed in the 
conditional Cftr T cell knockout mice may be directly related to the more vigorous 
TCR mediated calcium flux responses leading to an increase translocation of 
NFAT and higher induction of IL-13 in Cftr-/- T-cells. Exactly how CFTR 
dysfunction affects Ca2+ signaling in lymphocytes warrants further investigation 
and the convergence or overlap of other dysregulated pathways related to Cftr 
deficiency can not be ruled out. There is some evidence of CFTR dysfunction 
imparting elevated antibody secretion in B cell hybridomas; while these data do 
not explicitly assess CFTR function in B cells they do suggest that regardless of 
aberrant or normal B cell function in CF, the upstream events of T cell activation 
and helper function alone are enough to impart a polarized antibody response 
even in the presence of B cell with intact CFTR function.    
The main pathological features associated with cystic fibrosis are 
pancreatic cysts that lead to a reduction in the secretion of digestive enzymes as 
well as chronic airway infections most notably by pseudomonas. While it has 
been well established and recognized that impaired CFTR function adversely 
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affects the secretory epithelium, the role of CFTR in non-epithelial cells has 
received less attention or has largely eluded investigators. Certainly, if the CFTR 
alters the function of immune cells it should be expected to result in an aberrant 
immune response, which could further compromise patients. In summary our 
data identifies that CFTR dysfunction in T cells can in of itself lead to aberrant 
immune responses. Specifically we show how it skews responses to Aspergillus 
fumigatus, leading to a higher than normal IgE response. This observation itself 
is reminiscent ABPA, an otherwise rare but prevalent condition in the CF 
population. These findings represent a new and important cell population to 
investigate in order to try to prevent or ameliorate aberrant immune responses in 
people with cystic fibrosis.  Thus, current and future drugs targeting cystic fibrosis 
should determine if their benefits extend to this cell population, alternatively this 
also opens a new avenue to test small molecule modulators of immune response 
as a potential therapy for cystic fibrosis.  
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CHAPTER VIII: Additional Projects- IL-13 and IL-17e Receptor 
Therapy 
Introduction 
Asthma, a chronic disease involving inflammation of the airways, affects 
~5% of the population in the United States.  This includes ~10%-12% of children 
under age 18, according to 2003 data from the Centers for Disease Control.  
Asthma accounts for 12.7 million doctor visits, 1.2 million hospital outpatient 
visits, 1.9 million visits to the emergency room, 484,000 hospitalizations, and 
4,261 deaths per year. Although two general types of asthma medications are 
available, anti-inflammatory and bronchodilators, they only help control asthma 
as a life-long affliction; and long-term, daily medications are required over 
extended periods to achieve and maintain control of persistent asthma.  Thus, 
alternative therapeutic approaches are clearly warranted. Delivery of therapeutic 
proteins to the systemic circulation using gene therapy has the ability to provide 
durable expression after a single administration. Gene therapy offers the 
convenience of replacing frequent injections of recombinant proteins by intra-
venous treatment. Asthma and allergic rhinitis are almost invariably accompanied 
by elevated levels of IgE, and more importantly a genetic link between IgE levels 
and airway hyper-responsiveness has been established(203). It is known that the 
interaction of mast cell bound IgE with antigen leads to the release of vasoactive 
mediators, increased synthesis of Th2 cytokines and the production of 
leukotrienes and prostaglandins. This acute response leads to immediate-
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hypersensitivity in the lungs followed by mucous production, smooth muscle 
constriction and the eventual inflammatory infiltration. Thus, here we evaluate the 
possibility of using rAAV to express soluble cytokine receptors as a 
sequestration- treatment to allergic IgE driven responses in a previously 
characterized mouse model of exaggerated-IgE driven allergy. Current dogma 
suggests that asthma is driven by a dysregulated, Th2 biased immune responses 
to antigen. Our laboratory has previously characterized an allergic exaggerated-
IgE phenotype in CF mice where the CFTR defect causes an increased 
expression of IL-4 and IL-13. This immune aberration may lead to the increased 
sensitivity of CF patients to develop allergic disease, since approximately 50% of 
all CF patients have elevated levels of  serum IgE (204). Allergic reactions in CF 
patients complicate diagnosis and more importantly accelerate pulmonary 
deterioration. Interestingly 10-12% CF patients develop a unique allergic induced 
asthmatic response to common house mold Aspergillus fumigatus, known as 
allergic broncho-pulmonary aspergillosis (ABPA), which is characterized by an 
unusually high IgE response. Moreover, a recent study by Hartl et al. revealed 
the prevalence of a pulmonary Th2 immune response in P. aeruginosa-infected 
lungs of CF (176). Thus, the modulation of the pulmonary Th2 response may not 
only be beneficial for treating P. aeruginosa infections but may also lead to a 
decrease in the prevalence of allergic diseases associated with CF. Clinical 
asthma and ABPA are accompanied by elevated levels of Th2 cytokines such as 
IL-4 and IL-13 (205). Interleukin-13 is a pleiotropic cytokine that is secreted from 
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a wide array of cells including T cells (206), B cells (207), mast cells (208), 
basophils, natural killer and dendritic cells (209-211) with activities that partially 
overlap those of IL-4. This is partly explained by the fact that they share receptor 
components. Over expression of IL-13 in the mouse lung results in an intricate 
phenotype that recapitulates the classical symptoms of asthma. This includes 
goblet cell hyperplasia, mononuclear and eosinophil inflammation, subepithelial 
fibrosis, and airway hyper responsiveness.(212). In addition it has been shown 
that IL-13 is able to initiate B cell isotype switching for the production of IgE (213-
215).  
These features of IL-13, along with its major role in the CFTR-/- 
dependent ABPA model make it an interesting target for immune deviation for 
exaggerated IgE responses. As an alternative to targeting IL-13 we have also 
designed a soluble receptor antagonist for the recently discovered IL-17e (IL-25) 
cytokine. IL-17e is a member of the newly described IL-17 family, which is 
comprised of 5 members that share between 20-50% homology. Within this 
family, IL-17e is the only member to date that has been shown to promote the 
development of Th2 responses (216). In fact IL-17e treatment of mice resulted in 
the production of the cytokines IL-4, IL-13 and IL-5, extensive eosinophilia, 
increased serum IgE and striking histologic changes in the lung and gastro-
intestinal tract(216). In addition IL-17e was shown to activate NFkB and induce 
the production of IL-8 human cell lines(217). For these reasons this cytokine was 
also chosen as an attractive target for deviating the allergic response to 
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Aspergillus fumigatus. Targeting IL-17e with a soluble receptor is possible due to 
the recent identification of the IL-17 receptor homologue 1 (IL-17Rh1) which has 
shown to preferentially bind with IL-17e and somewhat with a lower affinity to IL-
17B (217).  
 
Materials and Methods 
CB-mIL-13Rα2-Fc: 
This construct consists of the extracellular domain (a.a 1-332) of the 
mouse IL-13Rα2 receptor fused with the CH2and CH3 including the hinge region 
(Fc) domains of a mouse IgG1 kappa antibody. The IL-13Rα2 receptor was 
synthesized by RT-PCR from RNA of mouse thymus. The RT-PCR was 
performed with the one step RT-PCR kit (Qiagen) using the following primers: IL-
13_sense 5’AGAATAAATGGCCTCGTG3’ and IL-13_antisense 
5’AATAACAGAAACACGGAAG3’. The resulting 1Kb fragment was the gel 
purified (Qiagen gel extraction kit). Subsequently, the CH2 and CH3 domains of 
a mouse IgG1kappa antibody were amplified by RT-PCR from RNA extracted 
from a mouse hybridoma cell line. A small Gly-Ser-Gly linker was added to the 5’ 
end of the PCR product. This product was also gel purified. The two fragments 
were then subjected to a blunt end ligation (T4 DNA ligase) at an equi-molar ratio 
this ligation was then subjected to 30 rounds of PCR using the forward IL-13 
primer and the reverse Fc primer to yield a 1770bp fragment. The fragment was 
then cloned into a TA vector backbone (Stratagene PCR 2.0), which was used to 
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transform Top10 cell for subsequent screening. Once the sequence of the fusion 
gene was verified by sequencing it was cloned into a CBA vector backbone for 
packaging. This was done by digesting the TA plasmid with the IL-13Rα2Fc 
fusion with Not1. The linearized plasmid was then treated with Klenow to fill in 
the 3’ overhang. The plasmid was then cut with Spe1 and the resulting 1777bp 
fragment was gel purified. To create a CBA backbone to clone the insert into, the 
pTR2-CBA-rIL-10 plasmid was cut with HindIII to linearize it and also treated with 
Klenow to fill in the 3’ overhang. Then it was cut with Nhe1 and the large 
~5300bp fragment was gel purified to serve as the pTR2-CBA-backbone for the 
IL-13Rα2Fc fusion insert. This two fragment were then ligated (T4 DNA ligase) at 
5:1 molar ratio (insert: backbone) to yield the final plasmid of 7061bp. 
 
CB-mIL-17Rh1-Fc: 
This vector is composed of the extra-cellular domain of the IL-17Rh1 (IL-
17BR) fused with the CH2and CH3 including the hinge region (Fc) domains of a 
mouse IgG1 kappa antibody. The methods used for the cloning of this fusion 
protein were the same as the ones describe above for the pTR-CBA- mIL-
13Rα2Fc vector with the exception of the primer used for the RT-PCR. The 
following primers were use to amplify the extra-cellular domain of the IL-17Rh1 
gene; IL-17Rh1-for 5’GGGCCATGTTGCTAGTGTTG3’ and IL-17Rh1-REV 
5’TCCCAAATGTAGGTCCCACTC3’.  
 
145
In Vitro Expression and Analysis of IL-17Rh1Fc:   
Expression of IL-17Rh1Fc was first investigated in cell cultures of 293 
human kidney epithelial cells. The cells were cultured in T-75 plates with 10mL of 
Dulbecco Modified Earls Media (DMEM) with 10% fetal bovine serum, FBS, 1% 
penicillin/streptavidin (Cellgro) in a 37°C humidified CO2 incubator until cells were 
90% confluent Expression of IL-17Rh1Fc was first investigated in cell cultures of 
293 human kidney epithelial cells. Cells were transfected at 90% confluency with 
Lipofectamine 2000. Forty-eight hours post transfection GFP cells were 
evaluated for expression and supernatants were collected for further western blot 
analysis.  
 
Serum IL-17Rh1Fc ELISA: 
Blood was collected upon sacrificing the mice, centrifuged in a serum 
separator and stored at –80C until analysis. Total IL-17Rh1Fc levels were 
measured with the BD IL-17Rh1 (IL-17BR) antibody pairs. They antibodies were 
used at the suggested concentration for coating and detection (BD Biosciences). 
Triplicate sera samples were used for each mouse. Tetramethyl-benzidine (TMB) 
substrate was used to develop the assay and was read at 450 nm with correction 
at 570nm on the VersaMax Micro Plate Reader (Molecular Devices). 
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Mouse strains: 
The primary CFTR knock-out strain used for these studies was the CFTR 
S489X -/- neo insertion in C57BL/6 mice developed initially at the University of 
North Carolina (186) and then modified with the transgenic overexpression of 
gut-specific expression of human CFTR from the fatty acid binding protein 
(FABP)- promoter in order to prevent intestinal obstruction and improve viability 
(187).  These mice have then been backcrossed 10 generations onto a C57BL/6 
mouse. 
 
Muscle Injection:   
For muscle administration of the rAAV1 vectors were injected into five to 
six week mice anesthetized with 3.5% isofluorane inhalation. 50µLs of viral 
vector suspension was administered percutaneously by intramuscular injection 
into the right or left gastrocnemius muscle two weeks prior (day -14) to Af-cpe 
sensitization. 
 
Aspergillus sensitization and challenge: 
Six to eight week old CFTR S489X -/-; FABP-hCFTR (+/+), and wildtype 
littermate mice were housed in the SPF mouse colony of the University of 
Massachusetts Medical School according to NIH guidelines and were allowed 
food and water ad libitum. All experimental procedures were approved by the 
IACUC of the University of Massachusetts Medical School. Animals were 
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sensitized to Aspergillus fumigatus crude protein extract (Af-cpe) (Greer 
Laboratories). Briefly, animals were administered with intraperitoneal (i.p.) 
injections of 200ug of Af-cpe extract dissolved in 100ul of PBS on days 0 and 14. 
Aerosol challenge was performed with 0.25 % Af-cpe for 20 min in a  30x30x20 
cm acrylic chamber using a jet nebulizer Pari model LC-D with an air flow of 6 
liters/min on days 28, 29 and 30.   
 
Serum IgE ELISA: 
Blood was collected on day 32 after sacrificing the mice, centrifuged in a 
serum separator and stored at –80°C until analysis. Total IgE levels were 
measured with the BD OptEIA ELISA (BD biosciences) triplicate sera samples 
were used for each mouse. Tetramethyl-benzidine (TMB) substrate was used to 
develop the assay and was read at 450 nm with correction at 570nm on the 
VersaMax Micro Plate Reader (Molecular Devices). 
Af specific ELISA was performed by coating a 96 well plates with 10ug of Af 
crude protein extract (Greer Laboratories) and detected using BD OptEIA IgE 
ELISA (BD biosciences) detection antibody.  
 
Cytokine Determination for Bronchoalveolar Lavage: 
Assessments of cytokine profiles from the Bronchoalveolar lavage (BAL) 
were performed using a commercially available multiplexed kit (Biorad Mouse 
Multi-Cytokine Detection System; Biorad Laboratories) and the Bioplex 
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Suspension Array System. Simultaneous measurement of 5 cytokines was 
performed: specifically, IL-2, IL-5, INF-G, IL-4 and IL-13. All assays were 
performed according to the manufacturer’s protocols. Cytokine concentrations 
were determined utilizing Bioplex software with four-parameter data analysis. The 
sensitivity of the assay is less than 10pg/ml and has a range from 0.2-32,000 
pg/ml with an inter and intra-assay coefficient of variance of less than 10%. 
 
Intracellular Staining of Cytokines for Flow Cytometry: 
Splenocytes were incubated for 3 hours with GolgiStop (BD Biosciences) 
in RPMI plus 10% Fetal Calf Serum at 37°C to block intracellular transport of 
cytokines.  The cells were then Fc blocked by CD16/CD32 antibodies for 5 
minutes at 4°C.  Cells were then stained for surface antigens (including CD4, 
CD44, CD11b, CD14, NK1.1) for 20 minutes at 4°C.  Cells were fixed and 
permeabilized for 20 minutes at 4°C with CytoFix/CytoPerm Buffer (BD 
Biosciences).  Anti-cytokine antibodies (IL-17a, IL-17e, IL-13 and IL-4) were 
stained for 25 minutes at 4C.  Cells were washed and then analyzed on BD LSR 
II using FACSDIVA software.  Analysis was done using FlowJo (Treestar) 
 
Statistical Analysis: 
All data were compared using an unequal variance two-tail student t test, 
unless stated otherwise. Data was considered statistically significant when 
p<0.05. 
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Results 
As previously described, we have recapitulated a peculiar exaggerated-
IgE phenotype in Cftr-/- mice in response to Aspergillus fumigatus crude protein 
extract (AF-cpe) sensitization and challenge. Although this model results in an 
increase in lung eosinophil recruitment and goblet cell hyperplasia in both 
wildtype and CF mice, it uniquely leads to a more vigorous IgE response in Cftr-/- 
mice.  In the original studies, we show that IL-13 mRNA levels in the lung of 
sensitized mice were more than 2-fold higher when compared to the control mice 
(179). Here we extend that finding and show that both wildtype and Cftr -/-  mice 
have substantial increase in the production of IL-13 in NK1.1+ (NK-cell marker) 
and CD14+ (macrophage marker) cells. Figure 8.1 depicts the change in number 
and type of cells expressing IL-13 intracellularly; where unsensitized Cftr-/- or 
wildtype mice served as baseline controls for IL-13 expression. Curiously, while 
IL-13 levels are detected in CD4+ cells in wildtype mice after Af-cpe sensitization 
and challenge, we only observed an increase in this cell population after Af-cpe 
challenge in Cftr-/- mice. The prominent increase of IL-13+ cells in this model 
along with the newly described role for IL-17e in regulating IL-13 prompted us to 
attempt immuno-modulating the exaggerated-IgE phenotype targeting IL-13 and 
IL-17e with soluble receptors.  
To create the soluble receptor fusion proteins, the extracellular domains 
for the IL-13Rα2 (a.a. 1-332) and for 17Rh1 (a.a. 1-489) were cloned in frame 
using a linker with the mouse IgG1 Fc gene containing the CH2, CH3 domains as  
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Figure 8.1 Overexpression of IL-13 in Cftr-deficient mice after ABPA 
Intracellular staining for the number of cells expressing IL-13 intracellularly after 
ABPA, graphed as a percent change over unsensitized animals. Gray bars depict 
wild-type animals whereas black bars are Cftr−/− mice -deficient animals. The 
number of positively gated cells from NK1.1, CD14, and CD4 divided by the 
lymphocyte gate determined by FSC and SSC and multiplied by the percent IL-
13+ of that population. N = 5 except CFTR wild-type ABPA which has an N = 6. 
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well as the hinge region to facilitate the formation of dimers (Figure 8.2A). 
Although there has not been a published delivery of the IL-13Rα2Fc soluble 
receptor with rAAV vectors, the characterization and function of the protein have 
been previously reported by Willis-Karp et al in a mouse model of ovalbumin 
induced asthma(218). To our knowledge the use of a soluble receptor for IL-17e 
has never before been tested, thus it was imperative that its function be 
evaluated in vitro before administration in vivo. To determine if the fusion 
construct was expressed and secreted, HEK-293 cells were transfected with CB-
IL-17RH1Fc, CB-IL-13Rα2Fc or CB-GFP; the latter two constructs being 
controls. Forty eight hours after the transfection, the supernatants were collected 
and run on a western blot assay.   
As shown in lane 1 of Figure 8.2B, detectable protein was secreted into 
the media of the transfected HEK-293 cells. There are two prominent bands that 
were observed when probed with the antibody against IL-17Rh1 receptor.   One 
of the bands is in line with the expected size of the fusion protein (~58kD) and 
the second band is above 100kD.  This second band may be representative of 
two fusion protein monomers dimerizing through the hinge region in the Fc 
portion of the soluble receptor (Figure 8.2A). Supernatants from cells transfected 
with CB-IL-13Rα2Fc do not contain a soluble receptor detected by antibody 
raised against the mouse IL-17Rh1 (lane 2 on Figure 8.2B).  
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Figure 8.2 IL-17Rh1Fc fusion protein is stable and efficiently secreted 
(A) Illustration of soluble receptor fusion protein. The extracellular domains of IL-
17e or IL-13 are fused to the CHCH3 domains of a mouse IgG1κ antibody. (B) 
Western blot of IL-17RH1fc protein. Supernatants from transfected HEK-293 
cells were blotted with an anti-IL-17Rh1 antibody. Lane 1: IL-17Rh1Fc 
supernatants; lane 2: IL-13Rα2Fc supernatants; and lane 3: protein ladder. (C) 
Total serum IL-17RhFc levels after rAAV1 administration. Total serum IL-17RhFc 
levels in CFTR−/− mice analyzed by ELISA from mice receiving either AAV1-GFP 
or AAV1-IL-17Rh1Fc (low and high dose). Results are reported as group mean + 
SEM (N = 5) **P < 0.05 
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Figure 8.2 IL-17Rh1Fc fusion protein is stable and efficiently secreted 
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To further determine if the IL-17Rh1 receptor Fc fusion protein would be 
secreted in vivo, we packaged rAAV1 vectors expressing IL-17RH1Fc and 
injected mice at two different doses. The first cohort of mice received either 
rAAV1CB-IL-17Rh1Fc or rAAV1CB-GFP at a dose of 1.0x1011 rAAV vector 
genomes (vg) per mouse and the second cohort at a dose of 3.0x1011 vg. A dose 
dependent detection of IL-17Rh1Fc was observed in the serum of these mice 
three weeks post injection, with the lowest levels receiving rAAV1-GFP and over 
a 200-fold increase in the mice injected with 3.0x1011 vg of rAAV1CB-IL-17Rh1Fc 
(Figure 8.2C). The serum from mice injected with CB-GFP also showed basal 
levels of soluble IL-17Rh1, which can be interpreted as the endogenous level of 
IL-17Rh1 protein. Endogenous protein present in the serum is supported by the 
evidence of an alternative splice variant of the protein that is secreted as a decoy 
receptor.  
A modified indirect ELISA was used to determine that the secreted IL-17Rh1Fc 
soluble receptor would be effective at binding IL-17e. A flat bottom 96 well plate 
was coated with different concentrations of IL-17e protein and subsequently the 
supernatants from the HEK-293 cell transfections of either the IL-17Rh1Fc or IL-
13Rα2Fc plasmids were incubated on the plate with IL-17e protein coated wells. 
An HRP conjugated secondary antibody directed against Fc portion of the 
soluble receptors was used to detect if the soluble receptors bound to the wells. 
Thus, the secondary antibody would detect only supernatants that contained FC 
fusion proteins able to bind IL-17e. As shown in Figure 8.3 there was a  
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Figure 8.3 Binding capacity of IL-17RhFc 
Ninety-six well plated were coated with different amount of IL-17e protein. Cell 
supernatants from IL-17Rh1Fc and IL-13Rα2Fc cell transfections were incubated 
in the IL-17e coated wells, after washing an HRP-conjugated mouse anti-IgG 
(able to bind the Fc portion of the fusion proteins) was used as to analyze the 
binding capacity of the supernatants to IL-17e. 
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correlation between the amounts of IL-17e coated on the plate and the signal 
absorbance from supernatant of the IL-17RH1Fc transfection only, whereas 
supernatants containing the IL-13Rα2Fc protein did produce an appreciable 
signal. 
Subsequent to the in vitro analysis, the IL-17Rh1Fc and the previously 
characterized IL-13Rα2Fc constructs were packaged into rAAV1 vectors for 
intramuscular administration in CFTR-/- mice.  The mice received IL-13Rα2Fc, 
IL-17Rh1Fc or CB-mSCAD expressing vectors at a dose of 1.0x1011 rAAV 
particles per mouse. Mouse SCAD, short chain acetyl CoA dehydrogenase 
(mSCAD), was used as a control instead of GFP because the foreign protein 
could potentially skew the Th2 response in favor of a Th1, CTL response in order 
to clear cells expressing GFP, thus inadvertently lowering IgE levels. 
Recombinant AAV was administered two weeks prior to Aspergillus fumigatus 
sensitization and challenge, to allow for vector uncoating, second strand 
synthesis and gene expression. Two weeks post i.m. delivery of the therapeutic 
soluble receptors the mice were subjected to the previously described 
exaggerated-IgE allergy model, which consists of a series of i.p. injections with 
Aspergillus fumigatus crude protein extract (Af-cpe) followed by airway 
challenges with nebulized Af-cpe (179, 180).  
To determine whether the therapies offered protection from the B cell 
isotype switching into an IgE mediated allergic response; the serum samples 
were evaluated for total IgE levels. As identified in Figure 8.4A the total  
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Figure 8.4 Reduction in circulating IgE levels after soluble receptor therapy  
(a) Total serum IgE levels after intramuscular rAAV delivery and Af-cpe 
sensitization and challenge. (b) Cftr−/− mice were injected with rAAV1-IL-
17Rh1Fc, rAAV1-IL-13Rα2Fc, rAAV1mSCAD, and rAAV1-GFP. Total Serum IgE 
in the Af-sensitized mice was measured by ELISA. Serum IgE levels specific for 
Af-cpe. N = 5 Results expressed as a mean + SEM **P < 0.05, ++ P < 0.1  
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circulating serum IgE levels were about 30-40% lower in mice receiving either of 
the two soluble receptors, this is comparable to the decrease we have observed 
in other studies using IL-10 as means to reduce IgE responses by 
immunomodulation (219). Further analysis of Af-specific IgE responses revealed 
that both soluble receptors were able to completely abrogate this response as 
detected by our assay (Figure 8.4B). This is in contrast to the Af-specific IgE 
levels observed in the mSCAD control injected mice.    
  In order to determine if the systemically circulating soluble receptors were 
having an effect locally in the lung, bronchoalveolar lavages (BALs) from the 
three vector treated groups were analyzed for various cytokines. As shown in 
Figure 8.5, the BALs of mice receiving the IL-13 soluble receptor had very high 
levels of IL-13 in the lungs while there was a slight but not significant decrease in 
the IL-13 levels between the mSCAD group and the IL-17Rh1Fc treated group. 
Furthermore the BAL analysis revealed that both of the soluble receptor 
treatments were significantly effective at lowering the KC response to Af-cpe in 
the lung (Figure 8.5). Also shown in Figure 8-5, IL-17Rh1Fc therapy resulted in  
downregulation of IL-5 whereas IL-13Rα2Fc therapy was not as statistically 
significant (Figure 8.5). IL-5 is an important cytokine involved in the maturation 
and recruitment of eosinophils. Consistent with this role, there was a decrease in 
the eosinophil infiltration found in the BALs from the lungs of the IL-17Rh1Fc 
treated mice (Table 8.1). 
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Figure 8.5 Cytokine levels in the BAL of mice treated with rAAV1 
expressing; IL-13Rα2Fc, IL-17Rh1Fc, or mSCAD.  
N = 5. Results expressed as a mean + SEM **P < 0.05.  
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Table 8.1 Proportions of inflammatory cells in the BAL 
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Figure 8.6 Intracellular cytokines produced after receptor agonist treatment 
Cells were stained for surface markers and intracellular cytokines using 
fluorescently conjugated antibodies that were detected by FACS analysis. CD4+ 
staining cells were gated and are depicted by the black bars; CD11b+ staining 
cells were gated and are depicted by the gray bars. IL-17Rh1Fc and IL-13Rh1Fc 
receptor agonist-treated mice cytokine expression after ABPA treatment are 
graphed as a percent change over the SCAD-treated control. (a) IL-4 staining, (b) 
IL-13 (c) IL-17a, and (d) IL-17e. n = 6 per group. 
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The broader effect on cytokine responses from mice receiving IL-17Rh1Fc was 
also observed from studying the splenocytes by flow cytometry after intracellular 
cytokine staining (Figure 8.6).  The Th-2 cytokines, IL-4 and IL-13 and IL-17 
family members, IL-17a, IL-17e intracellular cytokines were measured from 
soluble receptor treated mice and compared to mSCAD treated controls.  Th-2 
cytokines and IL-17 cytokines were reduced in both CD4 positive cells and 
CD11b positive cells treated with the IL-17e antagonist (Fig. 8.6).  The IL-13 
antagonist had minimal effect on the levels of the Th-2 cytokines as well as the 
IL-17 cytokines in the CD11b positive population of cells.  Curiously, the CD4+ 
population of mice treated with the IL-13 antagonist showed an increase of IL-4, 
IL-13 and IL-17a, with little to no change in IL-17e (Fig.8.6).  In contrast to IL-
13Rα2Fc treatment the IL-17Rh1Fc soluble receptor seems to be inhibiting IL-
17e signaling which may be acting upstream of both CD4+ and CD11b+ cells as 
observed by the decrease in cytokines in these cells (Fig 8.6). To determine what 
cell types could be the source of IL-17e in this ABPA model we compared 
splenocytes from Cftr-/- and Cftr+/+ mice before and after Af-cpe sensitization 
and challenge. As identified in Figure 8.7, we detected only slight differences in 
the levels of IL-17e between Cftr-/- and Cftr+/+ mice with a modest reduction in 
the percent of IL-17e positive cells Cftr-/- mice after Af-cpe challenge. More 
importantly we identified that CD14+ macrophages are a significantly more 
abundant source of IL-17e than CD4+ T cells (Figure 8.7). 
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Figure 8.7 Expression of IL-17e in CD14+ and CD4+ cells 
Intracellular staining for IL-17e with and without ABPA. (a) Graph of the mean 
percent IL-17e+ cells. n = 5 except Cftr+/+ ABPA which has a n = 6. Gray bars 
are CD4+ cells expressing IL-17e; black bars are CD14+ cells expressing IL-17e. 
Error bars are SE. (b) Representative dot blot of data depicted in a. Activation 
marker CD44 staining is on the x axis, IL-17e is on the y axis. CD14+ gated cells 
are on the top; CD4+ cells are on the bottom. Cells without ABPA are on the left 
and ABPA cells are on the right. 
164
Discussion 
These studies extend the potential utility of rAAV vectors for gene therapy 
targeting allergic disease and offer another example of the use of these vectors 
for the expression of therapeutic proteins designed to deviate allergic immune 
responses.  The experiments described here compared the efficacy of the 
neutralization of IL-17e and IL-13 with a single intramuscular injection of rAAV 
vectors expressing soluble receptors targeting these cytokines.  Intra-muscular 
injection of the vectors led to a significant production of protein as determined by 
the ELISA for serum levels of IL-17Rh1Fc. While the IL-13 soluble receptor was 
previously shown to bind IL-13 with high affinity, the IL-17Rh1 receptor has not 
been as well characterized. We demonstrated that fusing the extracellular 
domain of the IL-17e receptor to the Fc portion of a mouse IgG1 antibody 
resulted in stable secreted soluble receptors able to bind IL-17e protein. 
Intramuscular delivery of rAAV vectors resulted in the reduction of total IgE levels 
by both IL-13Rα2Fc and IL-17Rh1Fc soluble receptor therapy. When total IgE 
levels were analyzed, the 13Rα2Fc treated mice had a more significant 
reduction; however, when Af-specific IgE was analyzed it was evident that both 
soluble receptors were equally effective at completely abrogating the antigen 
specific IgE response.  
Further characterization of the effects of the soluble receptors was 
performed by looking at the cytokine levels in the lung compartment. Analysis of 
the BALs unexpectedly revealed that neutralization of IL-13 with IL-13Rα2Fc led 
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to higher levels of IL-13 in the lung. It is possible that IL-13 may act as a negative 
regulator of its own production, so interrupting this negative feedback loop may 
be causing cells in the lungs to secrete more IL-13. It is also possible, that the 
soluble receptor may be acting as depot or reservoir for IL-13, which would likely 
extend the half-life of IL-13 and thus artificially increase its concentration. In this 
scenario, although there is a higher concentration of IL-13, the cytokine would be 
mostly bound to the decoy receptor and thus would have little biologic activity. 
This scenario is far more likely taking into account that there was no increase in 
goblet cell hyperplasia accompanying the increase the IL-13 levels in the lung 
(data not shown). In fact the increase in the IL-13 has also been documented 
before in a model of helminth infection that employed IL-13Rα2 protein as a 
therapy (220). While IL-17Rh1Fc treatment did not seem to reduce the levels of 
IL-13 in the lung compartment, both treatments reduced levels of KC, a 
chemokine that has been previously shown to be upregulated in CF and has 
been implicated in pulmonary neutrophil mediated inflammation. However more 
importantly for allergy and asthma associated inflammation, IL-5 was significantly 
reduced in mice treated with rAAV-CB-IL-17Rh1Fc. Since IL-5 is responsible for 
the recruitment and maturation of eosinophils, the reduction of this response is 
also important for control of allergy driven inflammation. As shown in Table 8.1, 
this reduction in IL-5 was accompanied by a reduction in BAL infiltration of 
eosinophils in the IL-17Rh1Fc treated group. The reduction in eosinophil 
recruitment by dampening IL-5 and the prevention of Af-specific IgE responses 
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with IL-17Rh1Fc hint that a broader effect is achieved by targeting IL-17e rather 
than IL-13.  In fact when comparing intra-cellular cytokine staining of CD11b+ 
monocytes and CD4+ T cells from these mice in comparison to control treated 
mice, it was determined that IL-17Rh1Fc treated mice had a significant reduction 
in IL-4, IL-13 and IL-17e in both cell populations.  In contrast, macrophages in 
mice treated with IL-13Rα2Fc did not show any significant changes in the 
production of IL-13, IL-17a or IL-17e and only a slight decrease in production of 
IL-4. Even more compelling are differences detected in CD4+ T cells, where IL-
13Rα2Fc treated mice have increased production of IL-13 and IL-4, again hinting 
at a feedback inhibition loop, which surprisingly led to an increase in the 
production of IL-17a.  
This phenomenon may partially be explained by the recent discovery that 
a functional IL-13 receptor is present on CD4+ Th-17 cells and that in the 
presence of IL-13 signaling IL-17 production is attenuated (221). In case the 
absence of IL-13 signaling may be causing an increase production of IL-17 
lending further proof that IL-13 may also be involved in the regulation of TH-17 
response. On the one hand the broader effect of IL-17Rh1Fc therapy achieved in 
this allergy model suggests that IL-17e is acting upstream of CD4+ T and B cells, 
and interferes with the signaling mediated by IL-17e dampening the cytokine 
production of Th2 CD4+ T cells thereby curbing downstream B cell isotype 
switching to IgE and Th2 cytokine mediated eosinophil mediated inflammation  
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(Figure 8.8). On the other hand this data seems to suggest that targeting IL-13 
signaling, which is mainly an effector cytokine, may be useful at inhibiting 
downstream processes such as B cell isotype switching but may not be helpful at 
curbing responses at the CD4+ T cell level (Figure 8.8). In fact it seems that 
reduced bioavailability of IL-13 seems to make CD4+Tcells increase the 
production of both IL-4 and IL-13. Having established that interfering with IL-17e 
signaling with a soluble IL-17Rh1Fc receptor may offer broader benefits for 
allergic driven pulmonary inflammation we tried to determine what cell type may 
be the primary source of this cytokine. To begin to elucidate what cells may be 
possible sources of the IL-17e in the ABPA model, we stained splenocytes for 
the production of IL-17e in both Cftr-/- and Cftr+/+ mice before and after 
Aspergillus challenge. As shown in the figure 7 it seems that the more abundant 
source of this cytokine is present in CD14+ monocytes as opposed to CD4+ T 
cells.  
In conclusion these studies demonstrate a marked therapeutic effect of IL-
13 and IL-17e immuno-neutralization with the use of soluble receptors fusion 
proteins delivered with rAAV. The striking abrogation of Af-specific IgE response 
from the two different therapies has important implications for the treatment of 
ABPA and other allergic diseases.  This data in combination with the IL-17e 
staining data in the ABPA model suggests that IL-17e is an innate cytokine that 
may help bridge and regulate the production of Th-2 cytokines.  IL-17e is 
substantially produced by CD14+ macrophage cells, and the receptor antagonist  
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Figure 8.8 Model of IL-17e and IL-13 Receptor Therapy 
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reduced production of IL-17a, IL-17e, IL-13 and IL-4 when compared to 
the SCAD control both in CD4+ T cells and macrophages. As discussed above, 
the IL-13 antagonist appears to have more downstream affects as illustrated by 
the BAL cytokine data and flow cytometry.  Although, IL-13 antagonists did not 
reduce Th-2 or IL-17 cytokines, it did greatly reduce total and Af-specific IgE 
responses.  Presumably the IL-13 antagonist blocks the IL-13 from signaling the 
B-cells to isotype switch to make IgE, whereas the IL-17e antagonist acts further 
upstream in preventing Th-2 and IL-17 signaling to T cells as well as B-cells.  
Future experiments should look at the possibility that interfering with the signaling 
of both cytokines in combination may produce a synergistic effect in decreasing 
allergic response to Aspergillus fumigatus as well as to other antigens. Finally, 
while these experiments are proof-of-concept animal studies, in light of recent 
data from intra-muscular delivery of rAAV1 vectors in humans it is conceivable 
that a single administration with rAAV1 could provide sustained serum levels of 
the recombinant soluble receptors for up to one year (222).  
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Final Remarks 
Altogether this work describes two different gene therapy strategies, (1) as 
gene replacement and (2) receptor mediated correction of aberrant signaling 
after antigen exposure, for two different diseases (Chapter 5, Chapter 8). It also 
describes methods of potentially new therapeutic options through novel 
transductions efficiencies (Chapter 3, 4) as well as a disease phenotype which 
had not been previously described for which therapy could be directed (Chapter 
7). 
Clearly in order to develop a therapy, the mechanisms of disease must be 
fairly well understood.  Chapter 8 investigates the role T-cells play in CF, which 
allow for better therapeutic options like those described in Chapter 7.  Using the 
knowledge gained from earlier work on acyl-CoA dehydrogenase therapies and 
disorders of long chain FAO, our hypothesis was designed to target the liver, 
cardiac and skeletal muscle.  In vector selection for those specific targets, we 
also discovered efficient transduction and expression of both the brown fat and 
the brain.  Finally, clinically relevant disease specific phenotypes were corrected 
by gene transfer to the liver, cardiac and skeletal muscle resulting in correction of 
VLCAD-/- mice.  
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